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 Death rates for breast cancer have steadily decreased in women due to early 
detection, such as mammography, and improved treatments. Despite the benefit of 
mammography, many women are not up-to-date on screening and do not receive timely 
follow-up after abnormal mammogram finding. Breast cancer is a major contributor to 
morbidity and mortality among women in South Carolina. To reduce the disproportionate 
burden of breast cancer and cervical cancer among women in South Carolina, the South 
Carolina Best Chance Network (BCN) was established to provide service delivery and 
ensures timely and complete diagnostic follow-up and treatment initiation for 
underserved women. 
 The purpose of this dissertation was to examine whether travel distance to the 
screening provider and mammography facility are associated with completion of 
abnormal mammography follow-up, breast cancer stage at diagnosis, and mortality 
among women in the BCN.  Women enrolled in BCN between 1996 and 2009 were 
included in the study. Cox proportional hazard modeling was used to assess the 
relationship between travel distance and time to resolution. Multivariable logistic 
regression was used to assess the association between travel distance and breast cancer 
stage at diagnosis. Cox proportional hazard modeling and Kaplan-Meier survival 
methods were used to determine breast cancer-specific and all-cause survival 
probabilities. 
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Women who lived farther from their diagnosing mammography facility had 
longer day to resolution compared to those who lived the closest (p=0.05). African 
American women had significantly longer day to resolution compared to European 
American women. There was no association between travel distance to the screening 
provider, mammography facility and breast cancer stage at diagnosis. There was also no 
association between travel distance and breast cancer-specific and all-cause mortality. 
 Travel distance from patient’s residence to the diagnosing mammography facility 
may have an impact on the completion of abnormal mammographic finding. However, 
living farther from the screening provider and mammography facility do not increase 
late-stage breast cancer at diagnosis and mortality among women in BCN. Support to the 
BCN program to expand services should be promoted to reduce the disparity in days to 
completion of abnormal mammographic finding. Capturing an accurate measurement of 
travel distance/time will help better understand whether location of the health facilities 
affects breast cancer outcome.  
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This chapter presents an overview of the problem; it begins with breast cancer 
statistics, mammography screening and utilization, follow-up after abnormal 
mammography, breast cancer stage at diagnosis, breast cancer problem in South Carolina, 
the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), and an 
introduction to Geographic Information System (GIS). It continues with the purpose and 
specific aims, and the significant of the dissertation. Lastly, it ends with a summary of the 
chapter. 
Statement of the Problem 
Breast Cancer Statistics 
Breast cancer is the most common type of cancer among women and ranks second 
as a cause of death from cancer in the United States (1).
 
 About 1 in 8 women born today 
will be diagnosed with breast cancer at some point during their lifetime (2). In 2012, the 
American Cancer Society estimates approximately 226,870 new cases and 39,920 deaths 
from breast cancer among women in the United States (1).  From 2002-2006, the age-
adjusted incidence of breast cancer was 121.8 per 100,000 women and the age-adjusted 
death rate was 24.5 per 100,000 women per year (3). Among women in the United States, 
the overall 5-year relative survival rate is ~90%, a significant improvement from 63% in 
the early 1960s (1).
2 
Mammography Screening and Utilization 
Death rates for breast cancer have steadily decreased in women due to earlier 
detection, such as mammography, and improved treatments (4-9). Mammography is the 
single most effective method of early detection for breast cancer. It can identify the 
cancer at an early stage, when treatment is more effective (1).  The American Cancer 
Society screening guidelines recommend that average-risk women aged 40 and older 
receive mammography screening on an annual basis (1). About 38%-54% of women do 
not maintain annual adherence to screening mammograms (10, 11), and only 49% having 
received screening when using a biennial schedule (11). Annual mammography with 
adequate follow-up is estimated to result in reductions in mortality ranging from 25% to 
44% (6, 7, 12-15). Mammography is a highly accurate screening tool, but like most 
medical tests, it does not have perfect sensitivity and specificity. Generally, reported 
positive predictive values ranges from 78% to 90% (1, 16, 17). One drawback of 
mammography is the false positive results. One large study found that over a 10-year 
period of annual mammogram screenings, the chance of having a false positive result was 
close to 50% (18).  
Despite the benefit of mammography, many women are not up-to-date on 
screening (10, 11, 19, 20) and in fact, mammography uses have been declining in the past 
years (10, 21-23). This indicator of inadequate screening is associated with late stage 
breast cancer at diagnosis (24-26), which contributes largely to survival and mortality. 
Factors associated with mammography utilization have been scrutinized in numerous 
studies, which includes patients characteristics, socioeconomic status, insurance status, 
having a primary health care provider, recommendations for screening from primary 
3 
health care providers, lack of transportation/or time and distance, language barriers, 
concern about the effects of radiation, and fear of cancer (27-36).  
Abnormal Mammography and Follow-up 
 Mammography screening for breast cancer reduces mortality from breast cancer 
when women receive timely follow-up and appropriate treatment (7, 15). Mammogram 
results are interpreted by radiologists using the American College of Radiologist Breast 
Imaging Reporting and Data System (BIRADS
TM
) categories: 0 – “incomplete”; 1-
“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious abnormality”; 5-Highly 
suspicious of malignancy”; and 6-“Known biopsy proven malignancy” (37). A category 
of 3, 4, and 5 will require additional diagnostic procedures to determine the presence or 
absence of the disease (37). About 9%-15% of women who receive mammography 
screening have abnormal finding that require further testing (38), and approximately 
30%-50% never return for follow-up testing (39, 40). Incomplete screening and delayed 
abnormal follow-up can negate the potential benefits of identifying breast cancer at an 
early stage, where treatment is more effective and cure is more likely. Though many 
factors predicting incomplete and delayed abnormal breast cancer screening follow-up 
have been examined (26, 39-50), none has looked at distance to mammography facilities 
and completion of abnormal breast cancer screening follow-up.  
Breast Cancer Stage of Diagnosis 
 Breast cancer stage at diagnosis is an important factor in survival and mortality. 
The 5-year relative survival rates among women whose breast cancer is diagnosed while 
in the regional stage are nearly four times greater than those of women whose cancer has 
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spread to distant (distant stage) lymph nodes or organs at the time of diagnosis (84% vs. 
23%) (2).   Studies consistently show that low-income, health insurance status, 
community poverty, and racial/ethnic minorities are more likely to be diagnosed with 
late-stage breast cancer (51-57). Over the past decades, researchers have also explored 
geographic proximity to health care or mammography locations and breast cancer stage at 
diagnosis (58-66), which has found to be an important predictor of breast cancer stage at 
diagnosis. 
Breast Cancer in South Carolina 
 In 2012, the American Cancer Society estimated 3,570 women in the state of 
South Carolina were diagnosed with breast cancer and about 18% of the diagnosed 
women died of the disease (1). Breast cancer is the most common cancer diagnosed and 
is the second largest cause of cancer deaths among women in South Carolina (67). 
Statewide, the age-adjusted incidence of breast cancer from 2002-2006 have remained 
stable at around 119 per 100,000 women (1), with a higher age-adjusted incidence among 
European American women compared to African American women (127.6 and 111.3 per 
100,000 women, respectively) (68). The burden of this disease is heavily on low income, 
uninsured African American (51, 69).  
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and 
South Carolina’s Best Chance Network (BCN) 
 Minority, uninsured, and lower socioeconomic status women often do not have 
access to early detection (28, 36). These women are less likely to utilize mammography 
screening (28-32, 36), less likely to have timely and complete follow-up after an 
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abnormal mammography screening (39-41, 44), more likely to be diagnosed with 
advanced-stage breast cancer (51, 54, 56), and have poorer survival (51-53). To reduce 
the disproportionate burden of breast cancer and cervical cancer among these women, the 
U.S. Congress authorized the National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP) in 1990 (70). Since then, the program has established service 
delivery and ensures timely and complete diagnostic follow-up and treatment initiation 
for underserved women screened through the program.  
South Carolina’s NBCCEDP, also known as the Best Chance Network (BCN), is 
a network of public and private partnerships with more than 250 health care providers 
offering screening and follow-up services to disadvantaged women in the State.  At close 
to 18% (71), South Carolina has one of the highest proportions of uninsured women in 
the nation, which majorities of these women are eligible to enroll in the program. The 
majority (60%) of the women in BCN are African American and reside in rural counties 
(72).  The BCN offers an unique opportunity to explore the relationship between distance 
to the provider, mammography facilities, and breast cancer morbidity and mortality 
among women with equal access to screening services.  
Geographical Information Systems (GIS)  
Geographical Information System (GIS) is a system designed to input, store, edit, 
retrieve, analyze, and output geographic data information (73). It allows individuals to 
view, understand, question, interpret, and visualize data in various ways that reveal 
relationships, patterns, and trends in the forms of map, reports, and charts (74). The 
application of GIS has been used by health care researchers for decades and in recent 
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years, it has grown rapidly. GIS can be a useful tool to help understand the spatial 
organization of providers, mammography facilities, and its relationship to access and 
utilization, breast cancer stage at diagnosis, and mortality. Understanding the 
geographical and social connections between providers and the locations of 
mammography facilities is important for developing effective healthcare interventions to 
reduce breast cancer morbidity and mortality.  
Purpose and Specific Aims 
 The purpose of this dissertation was to examine whether travel distance to the 
provider, diagnosing mammography facility, and closest mammography facility are 
associated with completion of abnormal mammography follow-up, breast cancer stage at 
diagnosis and mortality among women in South Carolina’s National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP), Best Chance Network (BCN). 
Aim 1: Determine the relationship between geographic proximity to the provider, 
diagnosing mammography facility, and closest mammography facility and completion of 
abnormal mammography follow-up among women in the Best Chance Network (BCN). 
Research Question 1: Are there associations between distance to the provider, 
diagnosing mammography facility, closest mammography facility, and completion of 
abnormal mammography follow-up among women in the BCN?  
Aim 2: Evaluate the role of distance to the provider, diagnosing mammography facility, 
closest mammography, and breast cancer stage at diagnosis among women in the BCN.  
Research Question 2: Does living further from the provider, diagnosing mammography 
facility, and closest mammography increase the risk of having advanced stage of breast 
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cancer at diagnosis among women in the BCN? Also, is there a difference by 
race/ethnicity? 
Aim 3: Evaluate the role of distance to the screening provider, mammography facility, 
and mortality among women in the BCN. 
Research Question 3:  Does living further from the provider and closest mammography 
facility increase the risk of breast cancer mortality among women in the BCN? Also, is 
there a difference by race/ethnicity? 
Significant of Research 
 Breast cancer is a major contributor to morbidity and mortality among women in 
South Carolina and nationally. Among other factors, timely follow-up of an abnormal 
mammogram and breast cancer stage at diagnosis contribute largely to breast cancer 
morbidity and mortality. This study examined some important predictors, distance to the 
provider, diagnosing mammography facility, closest mammography facility, and its 
relationship with completion of abnormal mammography follow-up and breast cancer 
stage at diagnosis and mortality among low socioeconomic status women in South 
Carolina. This study contributes to the understanding of population-level barriers to 
abnormal follow-up and breast cancer stage at diagnosis, which may guide policy 
development and the development of effective programs to reduce breast cancer 
morbidity and mortality.  From a recent review of the literature, there has been no study 
examining distance to the provider, mammography facilities, and its effect on completion 
of abnormal follow-up and breast cancer stage at diagnosis and mortality among women 
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in South Carolina. This study adds to the breast cancer disparities research in South 
Carolina. 
Summary 
 Among women in the United States, breast cancer is most common cancer and the 
second leading cause of death (1). The American Cancer Society estimated over 226,870 
women were diagnosed with breast cancer in 2012, and about 18% of them died of the 
disease (1).  Mammography is the single most effective screening tool for early detection 
of breast cancer. Mammography screening for breast cancer reduces mortality from 
breast cancer when women receive timely follow-up and appropriate treatment. With all 
the benefits of mammography, many women are not up-to-date on screening and not 
maintaining annual adherence to screening mammograms (10, 11, 19, 20).  
Breast cancer stage at diagnosis is an important factor in survival and mortality. 
Studies consistently show that low-income, health insurance status, community poverty, 
and racial/ethnic minorities are more likely to be diagnosed with late-stage breast cancer 
(53-59); Women with these factors are also less likely to utilize mammography screening 
(28-32, 36), less likely to have timely and complete follow-up after an abnormal 
mammography screening (39-41, 44), and have poorer survival (51-53).  Understanding 
the geographical and social connections between providers, mammography utilization, 
and the locations of mammography facilities are important for the development of 
effective healthcare interventions to reduce breast cancer morbidity and mortality. The 
objective of this dissertation was to examine whether travel distance to provider, 
diagnosing mammography facility, and closest mammography facility affect completion 
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of abnormal mammography follow-up, stage of breast cancer at diagnosis and mortality 
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BACKGROUND & SIGNIFICANCE 
This chapter presents a literature review of breast cancer, including Breast Cancer 
Incidence and Prevalence, Breast Cancer Risk Factors, Breast Cancer Morbidity and 
Mortality, and Breast Cancer Stage at Diagnosis. It follows with Mammography 
Screening Recommendations and Utilizations, Abnormal Mammography and Follow-up, 
Distance to Mammography Facilities and Breast Cancer Stages at Diagnosis, Breast 
Cancer Problem in South Carolina and the Best Chance Network (BCN), Geographic 
Information System and Measurement of Access to Health Care, and concludes with a 
summary of the chapter.  
Breast Cancer Overview  
Breast Cancer Incidence and Prevalence 
 Breast cancer is a type of cancer that starts in the breast where cells divide and 
grow without normal control. Among women in the United States, breast cancer is the 
most commonly diagnosed cancer and is the second cause of cancer-related mortality (1, 
2). About 12.1% of women born today will be diagnosed with breast cancer in their 
lifetime (3). The American Cancer Society (ACS) estimated 226,870 women in the 
United States were diagnosed with breast cancer and 39,920 died of this cancer in 2012 
(1).  From 2002-2006, the age-adjusted incidence of breast cancer was 121.8 per 100,000 
women and the age-adjusted death rate was 24.5 per 100,000 women per year (4). 
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The incidence of breast cancer has been unstable in the last decades; from 1975-
1980, the incidence decreased by 0.5% per year; between 1980-1987, the incidence 
increased by 4.0% per year, between 1987-1994, it decreased by 0.1% per year, between 
1994-1999, the incidence increased by 1.6% per year, and from 1999-2006, breast cancer 
incidence decreased by 2.0% per year (2). The rapid increase of breast cancer incidence 
between 1980 and 1987 is most likely attributed to widespread use of mammography 
screening and increased detection of breast cancers at an early stage. The decrease from 
1999-2006 may reflect reductions in the use of menopausal hormone therapy (MHT), 
following the publication of results from the Women’s Health Initiative in 2002, which 
found that women using estrogen plus progestin had a 24% increase risk for breast cancer 
(5-6).  
Breast cancer risk factors 
 There are several factors that are linked to breast cancer risk. Some factors affect 
risk greater than others and some are modifiable, while others are not. Some of the risk 
factors reported by the American Cancer Society include age, overweight, use of estrogen 
and progestin, physical inactivity, consumption of alcoholic beverages, high breast 
density, reproductive factors (long menstrual history, having no child, and having first 
child after age 30), family history of breast cancer, inherited genetic mutations in the 
breast cancer susceptibility genes BRCA1 and BRCA2, socioeconomic status, and 
race/ethnicity (1). 
 The risk of developing breast cancer increases with age. From birth through age 
39, the probability of developing breast cancer is 0.43% (1 in 233 women); 3.75% (1 in 
19 
27 women) for ages 40 to 49; 3.40% (1 in 29 women) for ages 60 to 69; and 6.50% (1 in 
15 women) for ages 70 and older (1). Obesity has shown to affect breast cancer risk. 
However, the risk is different for pre- and postmenopausal women; before menopause, 
obese women have a lower risk of developing breast cancer compared to healthy weight 
women. After menopause, being overweight increases the risk of developing breast 
cancer by 30 to 60%. (7-10). Postmenopausal hormones use, such as estrogen plus 
progestin, increases the risk of developing and dying from breast cancer (5, 6, 11-14). 
Beral et al. (14) found that women who use estrogen plus progestin for more than five 
years double their risk of developing breast cancer.  
 Physical activity is an important contributor to health outcome. For breast cancer, 
regular activity may help lower the risk (15, 16). In fact, regular exercise can lower breast 
cancer risk by about 20% (16). Studies have also shown that physical activity increases 
survival among women with breast cancer (17-18). Alcohol consumption is also 
associated with higher risk of developing breast cancer. The risk increases with the 
amount of alcohol a woman drinks. One large study found that daily consumption of 
about 10g (1 drink) was associated with a 9% increase in risk of breast cancer (19). 
Increasing the alcohol consumption to ≥30g/day (3+ drinks) was associated with a 43% 
increase in risk (19). 
 Breast density is the proportions of fat and tissue in the breast. Women with high 
breast density (greater tissue compared to fat) are at a higher risk of developing breast 
cancer (20, 21). One study found that women with 75% or more mammographic density 
reading had an odds of 4.7 (95% CI: 3.0-7.4) times the odds of breast cancer compared to 
women with less than 10% mammographic density (21).  
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 Reproductive factors are some of the strongest risk factors for breast cancer 
development and accounts for nearly 50% of all breast cancer cases (1). Studies have 
shown that reproductive factors, such as long menstrual history, having no child, and 
having first child after age 30, are all strong risk factors for breast cancer (22-24). 
Women who had their first child after age 30 were 1.27 times likely to develop ductal 
breast cancer, 1.79 times for lobular breast cancer, and 1.66 times more likely to develop 
tublar breast cancer compared to women who had their first child before age 20 (24).  
Inherited genetic mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 
can also increase a women’s risk for breast cancer; however, these mutations are rare (1% 
of the population) and accounts for 5%-10% of breast cancer cases (1).  Family history of 
breast cancer increases the risk of developing breast cancer as well. A woman who has 
one immediate relative (mother, sister or daughter) with breast cancer increases her risk 
by two times; and with more than one immediate relative with the cancer, it increase the 
risk to four times higher compared to those with no family history (25, 26).  
 Women with higher SES (high income and/or high education level) have higher 
risk of developing breast cancer (27). There are many factors that may contribute to this 
association. Women with higher SES are more likely to have child at a later age, have 
fewer children, and also are more likely to use postmenopausal hormones compared to 
lower SES women (28-29). On the other hand, women with higher SES are less likely to 
die from breast cancer. One study found that women with no education beyond high 
school were 1.39 times more likely to die from breast cancer compared to women who 
were college graduates (30). Among all race/ethnicity, European American women have 
the highest incidence of breast cancer. From 2004-2008, the incidence rate of breast 
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cancer among European American was 127.3 per 100,000 women compared to 199.9 per 
100,000 women for African American (3). However, African American women are more 
likely to die from breast cancer compared to European American women.  
Breast Cancer Mortality 
 In 2012, an estimate of 39,920 women died of breast cancer (1). Though it is the 
second leading cause of cancer mortality among women, death rates have steadily 
decreased in the past decades (1, 2). Women younger than 50 years of age had a larger 
decrease than women older than 50 years of age (3.2% vs. 2.0% per year, respectively) 
(1).  Early detection and improved treatment have contributed largely to this decrease in 
breast cancer and mortality in recent years.  
 Although overall death rates for breast cancer have declined in the past decades, 
the mortality rates differ among racial/ethnic groups and age groups. From 2002-2006, 
African American had the highest breast cancer death rates (33.0 per 100,000 women) 
compared to European American (23.9 per 100,000 women) (2, 3). Breast cancer deaths 
among African American women have also been declining at a slower rate compared to 
European American women (31). In the 1980s, death rates were similar for both African 
American and European American women; however, since the early 2000s, African 
American women had a 39% higher mortality rate compared to European American 
women (31). This disparity may be due to breast cancer tumor characteristics seen in 
African American. Breast cancers diagnosed in African American women are more likely 
to have higher grade, advanced stage, and an aggressive subtype, which all contribute 
largely to this mortality disparity (32, 33). Difference in access to and utilization of early 
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detection and treatments may also explain why African American women have higher 
mortality compared to European American women (34-36). 
 Age is also an important factor in breast cancer development and mortality. 
Women younger than 40 years of age have more aggressive breast cancer subtype, which 
is associated with higher mortality compared to older women (37, 38).  Premenopausal 
women are also more likely to have aggressive subtype and are more likely to die from 
breast cancer compared to postmenopausal women (39).  
 Among women in the United States, the overall 5-year relative survival rate is 
~90% (1). Survival rates vary considerably among racial/ethnicity, age, tumor 
characteristics, and social factors. The overall 5-year relative survival rate is much lower 
for African American women compared to European American women; from 1999-2006, 
the 5-year relative survival rate for breast cancer among African American women was 
78%, a 13% lower compared to European American women (1). This difference can be 
attributed to both later stage at diagnosis and poorer stage-specific survival among 
African American women.  From 2003-2007, the median age of mortality from breast 
cancer was 68 years of age (3). Majority (57.5%) of breast cancer mortality occurred in 
women 65 years old and above (3).   
Breast Cancer Stage at Diagnosis 
Stage of breast cancer is based on the size of the tumor, whether it has invaded 
nearby tissues, and whether it has spread within the breast or to other parts of the body 
(40). Breast cancer is categorized into stage 0 through stage IV. Stage 0 is carcinoma in 
situ, where the cancer cells have not spread outside of the ducts or lobules. Stage 0 is 
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classified into two types: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ 
(LCIS). DCIS is the earliest form of cancer where cells are still within a duct and have 
not invaded into the surrounding fatty breast tissue. LCIS is when abnormal cells are 
found in the lobules of the breast. It is usually not considered a cancer; however, it 
increases the risk of developing breast cancer. Stage 1 is the early stage of invasive breast 
cancer. Cancer in stage 1 has not spread to surrounding lymph nodes or outside of the 
breast. Stage 2 breast cancer is also considered an early stage cancer. Depending on the 
tumor characteristics, it divided into two stages: stages 2A and 2B. Stage 3 breast cancer 
is a more advanced stage of breast cancer. Stage 3 cancer is divided into three categories: 
Stage 3A, stage 3B, and stage 3C. Stage 3A is when the tumor is larger than 5 
centimeters in diameter and has spread to the axillary lymph nodes. Stage 3B tumor can 
be any size; however, it has spread to the axillary lymph nodes and possibly other lymph 
nodes in the body. Stage 3C is the more aggressive type, which is present in adjoining 
tissue such as muscles or skin. Stage 4 breast cancer is the most advanced and aggressive 
of all stages. In this stage, the cancer has spread to other organs or tissues of the body, 
and most often these are the bones, lungs, liver, and brain (40). 
The 5-year relative survival rates among women whose breast cancer is diagnosed 
while in the early stages have higher survival compared to those diagnosed in later stages. 
Among women diagnosed with breast cancer in stage 0, the 5-year relative survival rate 
is approximately 93% (41). Stage 1 has a 5-year relative survival rate of 88%, stage 2A 
81%, stage 2B 74%, stage IIIA 67%, stage IIIB 41%, stage IIIC 49%, and stage IV breast 
cancer has a 5-year relative survival rate of 15% (41). Breast cancer stage at diagnosis is 
an important factor in survival and mortality among women.  
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Studies consistently show that low-income, health insurance status, community 
poverty, and racial/ethnic minorities are more likely to be diagnosed with late-stage 
breast cancer and have poorer survival (42-48). Examining seven state registries, Byers et 
al. (43) found that among 4,844 women diagnosed with breast cancer, those living in the 
lowest SES areas had substantially increased risk of breast cancer mortality (HR= 1.59, 
95% CI:1.35-1.87) compared to women not in the lowest SES area. After adjusting for 
age and race/ethnicity, the risk of mortality was still significantly higher for women 
living in low SES areas (HR=1.33, 95% CI: 1.11-1.58). Clegg et al. (47) found from 11 
Surveillance, Epidemiology, and End Results (SEER) cancer registries that lower income 
women were statically significantly  associated with an increased risk of being diagnosed 
with a late-stage breast cancer (p=0.02). The odds for late-stage breast cancer for the two 
lowest income categories were 2.3 and 1.8 times higher than those women in the highest 
income group, respectively (47). The author also found that non-Hispanic black females 
were 2.2 times more likely to be diagnosed with late-stage breast cancer compared to 
non-Hispanic white females. Smith et al. (42) examined women participating in the 
National Breast and Cervical Cancer Early Detection Program and found that African 
American women with late-stage breast cancer at diagnosis and negative ER/PR hormone 
receptor were at increased risk of mortality compared to European American women. 
Barry and Been (46) conducted a study examining residential characteristics and late-
stage breast and cervical cancer among women in the SEER registries. They found that 
women in three major metropolitan SEER areas (Atlanta, Georgia; Detroit, Michigan; 
and San Francisco, California) that resided in economically and socially distressed or 
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medically underserved areas (MUAs) were more likely to have late-stage breast cancer at 
diagnosis compared to those women who were not in those areas. 
Mammography Screening Recommendations and Utilizations  
 Regularly breast cancer screening is the best way for women to reduce their risk 
of dying from breast cancer. In fact, death rates for breast cancer have steadily decreased 
in women due to earlier detection, such as mammography, and improved treatments (4-
9). Breast self-examination (BSE), clinical breast exam (CBE), and mammography are 
the most widely used methods for breast cancer screening.  
 Breast self-examination is done by a woman examining her own breasts to detect 
for possible lumps, changes in size or shape of the breast, or any abnormality of the 
breast. Clinical breast exam is examination by a health care provider, who uses his or her 
hands to feel for lumps or other changes in the women’s breast. A mammogram is an x-
ray screening of the breast. Inside tissues of the breast are examined for abnormal 
changes. Mammography is the single most effective method of early detection for breast 
cancer. It can identify the cancer at an early stage, when treatment is more effective (1, 
49). The American Cancer Society screening guidelines recommend that average-risk 
women aged 40 and older receive mammography screening on an annual basis; have 
clinical breast exam about every 3 years for women in their 20s and 30s and every year 
after age 40; and an annual breast self-exam as an option for women starting in their 20s 
(1).  
 Annual mammography with adequate follow-up is estimated to result in 
reductions in mortality ranging from 25% to 44% (50-55). Mammography is a highly 
26 
accurate screening tool, but like most medical tests, it does not have perfect sensitivity 
and specificity. Generally, reported positive predictive values ranges from 78% to 90% 
(1, 56, 57). One drawback of mammography is the false positive results. Elmore et al. 
(58) conducted a 10-year retrospective cohort study of breast-cancer screening and found 
that over the 10-year period of annual mammogram screenings among 2,400 women, the 
chance of having a false positive result was close to 50%.  
 Despite the benefit of mammography, many women are not up-to-date on 
screening (59-61) and, in fact, mammography uses have been declining in the past years 
(59, 62-64). About 38%-54% of women do not maintain annual adherence to screening 
mammograms (59, 60), and only 49% having received screening when using a biennial 
schedule (60). Inadequate screening is associated with late stage breast cancer at 
diagnosis (65-68), which contributes largely to survival and mortality. 
 Hahn et al. (66) found that among 829 women who had no mammograms in the 
past 5 years had 1.95 times the risk of developing stage III/IV breast cancer compared to 
those who had more than 2 mammograms in the past 5 years.  They also found that the 
risk was higher for African American women compared to European American women; 
African American women had an odds of 3.57 (95% CI=2.26-5.65) of having stage III/IV 
compared to European women. In a large prospective cohort of over 1 million women, 
Smith-Bindman el al. (68) found that among women who had at least one mammogram 
between 1996 and 2002, African American women had higher risk of developing 
advanced-stage breast cancer compared to European American women. 
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Factors Associated with Mammography Utilization 
 Factors associated with mammography utilization have been scrutinized in 
numerous studies, which includes patients characteristics, socioeconomic status, 
insurance status, having a primary health care provider, recommendations for screening 
from primary health care providers, lack of transportation/or time and distance, language 
barriers, concern about the effects of radiation, and fear of cancer (69-78). A systematic 
review of 221 studies by Schueler, Chu and Smith-Bindman (70) found that physician 
access barriers were associated with not obtaining mammography. Not having a 
physician-recommend mammography and having no primary care provider were found to 
be highly predictive factors for not obtaining mammography (OR: 0.16, 95% CI 0.08-
0.33 and OR: 0.47, 95% CI 0.39-0.57, respectively). Barr et al. (74) also concluded that 
the number of primary care and gynecology physician visits was strongly associated with 
having a subsequent mammogram.  
 Participation of healthcare facilities in encouraging breast cancer screening can be 
an important factor in increasing breast cancer screening.  Quinley et al. (77) compared 
mammography screenings among women attending health facilities that send annual 
mammography reminders to those women who attend health facilities that do not send 
reminders. They found that among women who attend facilities that send annual 
reminders, 74% of the women received a second mammogram within 18 months 




Abnormal Mammography and Follow-up 
 Mammogram results are interpreted by radiologists using the American College 
of Radiologist Breast Imaging Reporting and Data System (BIRADS
TM
) categories: 0 – 
“incomplete”; 1-“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious 
abnormality”; 5-Highly suspicious of malignancy”; and 6-“Known biopsy proven 
malignancy” (79). A category of 3, 4, and 5 will require additional diagnostic procedures 
to determine the presence or absence of the disease (79). Table 2.1 shows the BIRADS
TM
 
categories and recommendations for the categories.  
Table 2.1. Breast Imaging Reporting and Database System (BI-RADS
TM
) 
Category Meaning Follow-up 
Recommendations 
0 Assessment is Incomplete, 
need additional imaging 
evaluation 
Additional imaging are 
needed before a final 
assessment can be assigned 
1 Negative Routine annual screening 
mammography 
2 Probably benign Routine annual screening 
mammography 
3 Suspicious Initial short-term follow up 
(usually 6-month 
examination) 
4 Suspicious abnormality Biopsy should be 
considered 
5 Highly suspicious of 
malignancy 
Requires biopsy or surgical 
treatment 




About 9%-15% of women who receive mammography screening have abnormal 
finding that require further testing (80, 81), and approximately 30%-50% never return for 
follow-up testing (82, 83).  The patient, provider, and system can all contribute to 
adequate follow-up. Many factors contributing to inadequate or incomplete follow-up 
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have been examined (67, 84-100). These factors include: fear (100), language barrier (82, 
89), patient anxiety (85, 89, 93), age (90, 95, 96, 98, 99), cost (90, 93), lack of provider 
(100), having case management (88, 91, 92), ethnicity (84, 94-96, 99, 100), education 
(86, 96, 98), and income (97, 99).  
Though these factors may contribute largely to inadequate to abnormal-follow-up, 
there are inconsistent findings. Kerner et al. (87) found no association between SES 
variables and timely follow-up on abnormal mammography. One study looking at women 
participating in the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) also found no association between completion of recommended workup and 
race (99). Nevertheless, incomplete screening and delayed abnormal follow-up can 
negate the potential benefits of identifying breast cancer at an early stage, where 
treatment is more effective and cure is more likely.  Of the many factors predicting 
incomplete and delayed abnormal breast cancer screening follow-up that have been 
examined, none has looked at distance to providers, mammography facilities, and 
completion of abnormal breast cancer screening follow-up. This present study will 
examine this structural and environmental factor that could affect the delay and 
completion of abnormal mammography follow-up. 
Distance to Mammography Facilities and Breast Cancer Stages at Diagnosis 
 Studies consistently show that low-income, health insurance status, community 
poverty, and racial/ethnic minorities are more likely to be diagnosed with late-stage 
breast cancer (42-47). A multilevel approach using spatial methods has been widely used 
in breast cancer research to understand some of the disparities in morbidity and mortality.  
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A common spatial method that has been examined is spatial accessibility to healthcare 
facilities. Accessibility, such as long travel distance, can discourage women to seek 
routine preventive care or screening. In the past decades, researchers have explored 
geographic proximity to health care or mammography locations and breast cancer stage at 
diagnosis (101-109). However, finding has been inconsistent between the studies. There 
are six studies that found no association between travel distance to mammography and 
breast cancer stage at diagnosis (101-106); however, three studies found that there is an 
association (107-109). 
 Tarvo et al. (101) found no association between breast cancer stages at diagnosis 
and patients’ residential address to nearby mammography facilities in Chicago. In their 
study, breast cancer stage was categorized as in situ, local, and distant. They calculated 
distance using street network from the residential address of each cancer case to each 
mammography facility. Instead of using the closest mammography, the authors used the 
mean distance to the five closest mammography facilities. While the author tried to 
account for choice and constraints that may exist in mammography facility availability to 
individuals, they found no association between travel distance and breast cancer stages.  
 In Virginia, Schroen and Lohr (102) found no relevant relationship between travel 
distance to the nearest mammography facility and invasive tumor size. For the outcome, 
tumor size was used instead of cancer stages. Distance was calculated from patients’ 
home location to the nearest mammography facility. After adjusting for age, race, 
income, they found no association between travel distance and late stage breast cancer at 
diagnosis.  
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 Wang et al. (103) conducted a similar study in Illinois and found no statistically 
significant association between travel time to mammography facilities and stage of breast 
cancer at diagnosis. In this study, each cancer case was geocoded to the county and zip 
code of residence rather than patients’ residential address. They defined late-stage breast 
cancer as diagnosis in stages 2 through 7.  Though there was no association between 
travel time to mammography facilities and breast cancer stage at diagnosis, they did 
found an association between geographical access to primary care physician and late-
stage breast cancer. The authors noted the no association finding may be due to the 
homogeneous population (close proximity) to mammography. The average estimated 
travel time was fairly short in Illinois, which may conclude that travel time to 
mammography might not be a major issue in the studied population. This study has two 
limitations. First, they did not have information on patients’ mammography utilization 
and, therefore, could not calculate distance to the actual mammography that the patients 
actually use. Second, patients’ residence was geocoded to zip code centroids, which may 
not be an accurate estimate of travel time.  
 Three of the more recent studies from 2010-2011 also found no association 
between travel distance and breast cancer stage at diagnosis. A study in 2010 by Celaya 
et al. (104) found that among women in New Hampshire, there was no association 
between late-stage breast cancer and travel time to the nearest mammography facility. In 
this study late stage breast cancer was categorized at stages 2 and 4. They calculated 
proximity using both travel time and travel distance using road network and still found no 
association. They also found that urban/rural residence was not associated with late stage 
breast cancer in their population of study.  
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 Onega et al. (105) studied this association in Washington in 2011 and also 
reported no significant association between travel time and breast cancer stage. Women 
with breast cancer stage 1, 2A, and 2B were examined in their study. They examined two 
outcomes: stage of breast cancer (stage 2B as late stage) and tumor size (≥2cm as late 
stage). They used travel time (in minutes) instead of distance (in miles) like some of the 
previous studies. With different outcome and travel distance measurement, they still 
found no association between travel distance and breast cancer stage at diagnosis. One 
major limitation to this study was that patients were limited only to women with early-
stage breast cancer (1, 2A, and 2B).  
 One of the more recent study by Henry et al. (106) used 10 population-based state 
cancer registries (Arkansas, California, Iowa, Idaho, Kentucky, North Carolina, New 
Hampshire, New Jersey, New York, and Oregon) to study whether there is an association 
between travel distance and breast cancer stage at diagnosis. From the 10 cancer 
registries, there were 161,619 women in the study. Tumors that were in situ or localized 
stages were considered “early stage” and regional or distant stages were considered “late 
stage”. This is the first study to measure both travel distance from the patients’ residence 
to the closest mammography facility and to their diagnosing facility. They found no 
association to the nearest mammography facility. However, when using distance to the 
diagnosing facility, they found weak evidence that shorter travel time was associated with 
late stage breast cancer at diagnosis; however, the direction of the effect was the opposite 
of what is expected. The odds of having late stage breast cancer at diagnosis was lower 
for women with longer travel time to their diagnosing facility.  The odds of late stage 
breast cancer at diagnosis for women who lived 40-50 minutes from their diagnosing 
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facility was 0.83 times the odds for women who lived <10 minutes. The trend was similar 
as the distance from the diagnosing facility increased.  
 The first study to find an association between travel distance and breast cancer 
stage at diagnosis was conducted in Los Angeles by Gumpertz et al. (107). In this study, 
stage of breast cancer was categorized as “advanced disease” if the stage of breast cancer 
at diagnosis is regional with tumor diameter < 10 cm or as distant with any tumor size. 
They used Euclidean (straight line) distance from the patients’ census tract centroid to the 
nearest mammography facility. Distance was broken down into two categories: 10km vs. 
1km. After adjusted for neighborhood characteristics and tumor biology, distance from 
the census tract centroid to the nearest mammography facility was a significant predictor 
of advanced stage of breast cancer; however, this association was only found for Hispanic 
and White women. This study used census tract centroids to calculate the distance to the 
mammography facility, which may not be an accurate measurement of travel distance. 
They also did not use road network, therefore, distance calculated may be under 
estimated.  
 Another study that found an association between travel distance and breast cancer 
stage was done in Kentucky by Huang et al. (108) in 2009. Tumors that were in situ, or 
stage 1 or 2 were considered “early stage,” and tumors stage 3 or 4 were considered 
“advanced stage.” They calculated travel distances from patients’ zip code centroid to the 
nearest mammogram facility along the road network. Adjusting for various 
characteristics, they found that women living 15+ miles from the nearest mammography 
was 1.48 times more likely to have advanced stage of breast cancer at diagnosis 
compared to women who lived less than 15 miles. There are two limitations to this study. 
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First, this study assumes that women had access to mammogram centers closest to their 
homes, which may not always be true due to other circumstances. The other is using zip 
code centroids as patients’ place of residence; this may not accurately measure true 
residence, which may affect true distance calculation from home to nearest 
mammography facility. 
 The last and more recent study by Dai (109) in 2010 found that there is an 
association between travel distance and late-stage breast cancer at diagnosis in Detroit.  
In this study, early stage breast cancer was defined as “in situ” and “localized,” and late 
stage was defined as “regional” and “distant.” The author used zip code centroids of 
patients’ residence to calculate the distance to the nearest mammography and primary 
care facilities. Controlling for socioeconomic factors at ZIP code level, the author found 
that women living in areas with greater black segregation and poorer mammography 
access significantly increases the risk of late stage breast cancer at diagnosis. Compared 
to Wang et a. (103) who found association between primary care access and late-stage 
breast cancer, this study found no association between this relationship. Like previous 
studies, a limitation of this study is the use of ZIP code of residence at diagnosis and not 
using network road to calculate the distance. 
 All of these studies, except one (106), had no information on patients’ 
mammography utilization. Using the nearest mammography facility may not represent 
patient utilization. A patient may not utilize the nearest facility due to personal and 
neighborhood characteristics, such as hours of operation, insurance requirement, and 
location to work. Relying on the closest mammography facility may underestimate the 
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true travel distance between patients’ residence and actual mammography usage if the 
closest facility is not the one being utilized. 
 When mammographic facilities are not conveniently located, women may not 
have regular mammograms, which may result in diagnosis of breast cancer at later stage. 
Geographic proximity is an important factor in determining breast cancer stage at 
diagnosis; however, studies have found inconsistent association between this relationship. 
From the above studies, there were differences and similarity in the methodology used in 
examining breast cancer stage and travel distance to mammography facility. Even 
though, some studies used the more precise measurement of distance (patients’ residence 
at diagnosis and road network), they still found no association between breast cancer 
stage at diagnosis and travel distance. Others used zip code centroids to calculate the 
distance travel and found association between this relationship. The inconsistent results in 
the literature highlight the need for further research to determine whether women living 
further from mammography facilities are at an increased risk of having late stage breast 
cancer at diagnosis. This dissertation examines this relationship in South Carolina among 
women participating in the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP). 
Breast Cancer Problem in South Carolina and the Best Chance Network (BCN) 
South Carolina is a relatively rural state with approximately 30% African 
American (110). The poverty rate in South Carolina from 2008-2009 is about 20%, with 
African American having the higher rate compared to European American (35% vs. 13%, 
respectively) (110). At close to 18% (111), South Carolina has one of the highest 
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proportions of uninsured women in the nation, which is a strong predictor of breast 
cancer mortality and morbidity (27, 28, 30, 47). Along with the appalling statistics of the 
state, South Carolina has some of the highest cancer statistics in the nation, especially 
breast cancer morbidity and mortality (112, 113).  
In 2012, the American Cancer Society estimated 3,570 women in the state of 
South Carolina were diagnosed with breast cancer and about 660 women died of the 
disease (1). Breast cancer is most common cancer diagnosed and is the second largest 
cause of cancer deaths among women in South Carolina (112). Statewide, the age-
adjusted incidence of breast cancer from 2002-2006 have remained stable at around 119 
per 100,000 women (1), with a higher age-adjusted incidence among European American 
women compared to African American women (127.6 and 111.3 per 100,000 women, 
respectively) (114). The burden of this disease weighs heavily on low income, uninsured 
African American (42, 99).  
To reduce the disproportionate burden of breast cancer and cervical cancer among 
women, the U.S. Congress authorized the National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP) in 1990 (115). Since then, the program has established 
service delivery and ensures timely and complete diagnostic follow-up and treatment 
initiation for underserved women screened through the program.  
South Carolina’s NBCCEDP, also known as the Best Chance Network (BCN), is 
a network of public and private partnerships with more than 250 health care providers 
offering screening and follow-up services to disadvantaged women in the State.  South 
Carolina has one of the highest proportions of uninsured women in the nation, of which 
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majority of these women are eligible to enroll in the program. The majority (60%) of 
women in BCN are African American and reside in rural counties (111).  The BCN offers 
an unique opportunity to explore the relationship between distance to the provider, 
mammography facilities, and breast cancer morbidity and mortality among women in 
South Carolina.  
Geographic Information System and Measurement of Access to Health Care  
 Geographical Information System (GIS) is a system designed to input, store, edit, 
retrieve, analyze, and output geographic data information (116). It allows individuals to 
view, understand, question, interpret, and visualize data in various ways that reveal 
relationships, patterns, and trends in the forms of map, reports, and charts (117). The 
application of GIS has been used by health care researchers for decades and in recent 
years, it has grown rapidly. The capability of GIS has made it possible for health care 
researchers to spatially understand health issues such as health care distribution, access 
and utilization, disease risks related to environmental exposures, and morbidity and 
mortality, social demographic data, and morbidity and mortality (118-120).   
 In terms of health care accessibility, there are several measurements of 
accessibility. Distance to the nearest provider is one of the most commonly used 
measures of spatial accessibility in health care research. This is done by calculating the 
distance between patients’ residence or centroid of a ZIP code and census tract to the 
nearest health care provider. There are three commonly used methods to measure this 
distance: i) Euclidean or straight line distance; ii) travel distance along a road network; 
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and iii) travel time along a road network (both taking account of traffic and not taking 
account of traffic) (121, 122). 
 The Euclidean distance measures straight-line distance from two points of 
interests. These points can be points, lines or polygons (121). This method has its 
advantage and disadvantage. The key advantage of using this method is that it is easy to 
calculate. The disadvantage is that it does not take into account the transportation 
network or topography of an area that might lengthen the distance traveled from one 
point to the other.  
 Travel distance along a road network or street distance is based on the network of 
streets that would be traveled from one location to another (122). This method offers a 
more accurate measure of the actual path between two points; therefore, it provides a 
more realistic measure of actual distance traveled than the Euclidean method. Travel time 
or driving time is similar to travel distance between two points, but is based on driving 
time on a road network. This process utilizes information about road length and average 
travel speeds along street segments (122).  
 In geographical access to health services, travel distance and travel time along the 
road network are recognized as the more appropriate measures of the travel effort 
actually experiences than the Eulicudean distance, which does not take into account of 
physical barriers (e.g. rivers or hills) and patchy road network (123). In fact, Shalid et al. 
(124) found that Euclidean distance tends to underestimate road distance and travel time 
when measuring the distance between patients’ residence and health care facility.  
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Using GIS to estimate actual travel time by patients has shown good correlations. 
Haynes et al. (125) conducted a validation study comparing GIS estimates of travel 
distance with the actual times reported by 475 cancer patients who had travelled by car to 
attend clinics. The correlation between reported times and estimated travel times was 
0.87, which is a moderately strong association. They also found that straight line distance 
and reported travel was moderately strong correlation (r=0.85, p<0.001).  
 GIS can be a useful tool to help understand the spatial organization of 
mammography facilities and its relationship to access and utilization of mammography, 
breast cancer stage at diagnosis, and mortality. Understanding the geographical and social 
connections between mammography utilization and the locations of mammography 
facilities are important for developing effective healthcare interventions to reduce breast 
cancer morbidity and mortality. 
Summary 
 Among women in the United States, breast cancer is the most commonly 
diagnosed cancer and is the second cause of cancer-related mortality. In 2012, 226,870 
women in the United States were diagnosed with breast cancer and 39,920 died as a result 
of this cancer. From 1999 to 2006, breast cancer rates had decreased by 2.0% per year, 
which may be due to the reduction in use of menopausal hormone therapy. There are 
several factors that are linked to breast cancer risk. Some factors affect risk greater than 
others and some are modifiable, while others are not. 
Comparing to European American women, African American women had the 
highest breast cancer death rates (33.0 per 100,000 vs. 23.9 per 100,000). This disparity 
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may due to the breast cancer characteristics diagnosed among African American women. 
Breast cancer stage at diagnosis is an important factor in survival and mortality.  The 5-
year relative survival rates among women whose breast cancer is diagnosed while in the 
early stages have higher survival compared to those diagnosed in later stages. Regular 
breast cancer screening is the best way for women to reduce their risk of dying from 
breast cancer. In fact, annual mammography with adequate follow-up is estimated to 
result in reductions in mortality ranging from 25% to 44%.  
 Mammogram results are interpreted by radiologists using the American College 
of Radiologist Breast Imaging Reporting and Data System (BIRADS
TM
). A category of 3, 
4, and 5 will require additional diagnostic procedures to determine the presence or 
absence of the disease. About 9%-15% of women who receive mammography screening 
have abnormal finding that require further testing. The patient, provider, and system can 
all contribute to adequate follow-up. 
Travel barriers, such as long travel distance, can discourage women to seek 
routine preventive care or screening. A common measurement of spatial accessibility is 
travel distance or travel time from a residential place to the closest facility. Geographic 
proximity may be an important factor in determining breast cancer stage at diagnosis; 
however, studies have found inconsistent association between this relationship. The 
inconsistent results in the literature highlight the need for further research. 
 South Carolina has some of the highest cancer statistics in the nation, especially 
breast cancer morbidity and mortality. South Carolina also has one of the highest 
proportions of uninsured women in the nation. South Carolina’s NBCCEDP, also known 
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as the Best Chance Network (BCN), is a network of public and private partnerships with 
health care providers offering screening and follow-up services to disadvantaged women 
in the State. The BCN offers an unique opportunity to explore the relationship between 
distance to provider, mammography facilities, and breast cancer morbidity and mortality 
among women in South Carolina.  
 There are three commonly used methods to measure travel distance between two 
points of interest: i) Euclidean or straight line distance; ii) travel distance along a road 
network; and iii) travel time along a road network. GIS can be a useful tool to help 
understand the spatial organization of mammography facilities and its relationship to 
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This chapter describes the data source and methods that was used to conduct the 
study. The chapter begins with the study design and then goes on to describing the data 
source, participant inclusion criteria, outcome of interest, main exposure and covariates, 
and data analysis for each of the specific aims. Lastly, it ends with a summary of the 
chapter.  
Study Design 
 This study was a retrospective cohort study that covers a period of 14 years 
between 1996 and 2009. The purpose was to investigate travel distances (to the screening 
provider, diagnosing mammography facility, and closest mammography facility) and 
completion of abnormal mammography follow-up, breast cancer stage at diagnosis, and 
mortality among women participating in the Best Chance Network. The present study 
used secondary data, collected for billing and national surveillance purposes, and no 
primary data collection among participants was required.  Of note, all analytic work 
requiring the use of protected health information (e.g. distance calculation) was 
completed on-site at the South Carolina’s Department of Health and Environmental 
Control (SC DHEC).  Only a de-identified dataset was released from DHEC for analysis.  
Neither the PI nor any other investigators were able to view identifiable or restricted data.    
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Data Source and Data Analysis for Aims 1, 2 and 3 
Aim 1: Determine the relationship between geographic proximity to the screening 
provider, closest mammography facility, diagnosing mammography facility, and 
completion of abnormal mammography follow-up among women in the Best Chance 
Network (BCN). 
Research Question 1: Are there associations between travel distance to the screening 
provider, closest mammography facility, diagnosing mammography facility, and 
completion of abnormal mammography follow-up among women in the BCN?  
 For aim 1, the dataset source came from the South Carolina Best Chance 
Network. The program is part of the National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP), which began in 1990 (1). It is a network of public and private 
partnerships with more than 250 health care providers offering service delivery and 
ensures timely and complete diagnostic follow-up and treatment initiation for 
underserved women screened through the program. Over the past five years (2005-2010) 
the program had served over 36,500 women in the State (2). 
Mammogram results are interpreted by radiologists using the American College 
of Radiologist Breast Imaging Reporting and Data System (BIRADS
TM
) categories: 0 – 
“incomplete”; 1-“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious 
abnormality”; 5-Highly suspicious of malignancy”; and 6-“Known biopsy proven 
malignancy” (3). A category of 4 and 5 will require additional diagnostic procedures to 
determine the presence or absence of the disease. All participants with abnormal 
mammography are provided with case management services, which work with the 
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participant to help her receive follow-up diagnostic services within 60 days. In the last 
five years (July 2005-June 2010), the Best Chance Network performed over 40,100 
mammography screening and 5,241 of them were abnormal or incomplete results (2).  
Inclusion Criteria for Aim 1 
Women included in the dataset include:  
 Enrolled in BCN between 1996 and 2009 
 Having an abnormal mammogram, a BIRADS category of 4 or 5 
 Having diagnostic work-up planned for breast cancer 
 Having status and date of final diagnosis record 
 Known screening provider 
 Residence address is not a PO Box address 
Aim 1 Outcome of Interest 
 The dependent variable for aim 1 was time-to-resolution or completion of 
abnormal mammogram follow-up. The measure of time was the number of days between 
the first mammogram and the date that the follow-up status was finalized (work-up 
completed, refused, or lost-to-follow up). A completed work-up is designated when the 
diagnostic testing is complete and a final diagnosis has been made (benign or malignant 
breast cancer). Refused work-up indicates a woman had her diagnostic work-up 
performed by another provider. A loss-to-follow up status indicates that the woman died, 




Aim 1 Main Exposure and Covariates 
 There were three main exposure variables for aim 1: There were three main 
exposure variables of interest: travel distance to the screening provider, travel distance to 
the diagnosing mammogram facility, and travel distance to the nearest mammography 
facility. All three distance calculations were calculated along a road network from 
patients’ residence to the facility of interest.   Confounders and effect modifiers included 
age, race, previous mammogram, yearly family income, and insurance status at time of 
visit with the BCN. 
Data Analysis 
GIS Approach 
 Mammography facilities, screening providers, and patients’ residence were 
geocoded to the exact street address of location. The geocoded addresses (latitudes and 
longitudes) were used to calculate the three distances (in miles) between residence and 
the diagnosing mammography facility, screening provider, and the nearest 
mammography facility. All geocoding of addresses was done using ArcGIS (ESRI, 
Redlands, CA). Distance calculations were performed by using the Network Analyst tool 
function in ArcGIS. Once the distance variables were calculated, a de-identified dataset 







 Descriptive statistics were calculated for all characteristic variables. Chi-square 
test and t-test were used to examine the bivariate associations between demographic and 
race variables. The median days and distances from the abnormal mammogram to 
diagnostic resolution were assessed with Kaplan-Meier survival method. Wilcoxon test of 
equality over strata was used to test for statistical significant between the distances.  
 Cox proportional hazard modeling was used to assess the relationship between 
work-up completion and travel distance to the screening provider and mammography 
facility.  Women whose final status was recorded as refused or loss-to-follow up were 
considered censored observations. The proportional hazards assumption was examined 
through the logarithm of negative logarithm of survival probability with logarithm of 
time and the Schoenfeld residuals were further evaluated to confirm that there were no 
violations of the assumption. All analyses were performed using SAS version 9.3 (Cary, 
NC). A two-sided alpha level of 0.05 was used to determine significant for all tests.  
Aim 2: 1) Investigate whether travel distance to the screening provider and 
mammography facility are associated with breast cancer stage at diagnosis among 
women participating in South Carolina’s BCN, 2) examine whether there are racial 
disparities in the distribution of breast cancer stage at diagnosis among BCN 
participants, and 3) examine whether there are any differences in the distribution of 




Research Question 2: Does living further from the screening provider, diagnosing 
mammography facility, and diagnosing mammography facility increase the risk of 
being diagnosed with a more advanced stage of breast cancer at diagnosis among 
women in the BCN? Also, is there a difference by race/ethnicity? Are there 
significant differences in the distribution of breast cancer stage at diagnosis among 
BCN and non-BCN women in the State of South Carolina? 
 The South Carolina Central Cancer Registry is a population-based data system 
that collects cancer statistics in the state of South Carolina. From the last audit, the 
registry has a completeness rate of 96.9% and an accuracy rate of 96.4%, both of which 
exceeded the national standard of 95%. SCCCR also maintains a “Gold Certification” 
from the North American Association of Central Cancer Registries (NAACCR) (4). 
Thus, the data are of high quality, validity, and completeness.  For aim 2, the dataset 
source came from both the BCN and SCCCR. SCCCR did the data linkage to the BCN 
data. This data linkage allowed the identification of BCN breast cancer cases in SCCCR, 
the screening providers, and the diagnosing mammography facility.  To compare breast 
cancer stage at diagnosis between BCN and non-BCN women, we identified non-BCN 
women with breast cancer from SCCCR between 1996 and 2009. 
Inclusion Criteria for Aim 2 
Women included in the dataset include:  
 Is a first primary breast cancer case in SCCCR between 1996 and 2009 
 Enrolled in BCN between 1996 and 2009 
 Known breast cancer stage at diagnosis  
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 Known screening provider 
 Residence address is not a PO Box address 
Aim 2 Outcome of Interest 
 The outcome of interest was breast cancer stage at diagnosis. Using the 
Surveillance Epidemiology and End Results (SEER) Summary Staging guide, breast 
cancer stages were dichotomized into ‘early stage’ and ‘late stage’; In situ and localized 
(confined to primary site) stages were considered ‘early stage’ and regional (spread to 
regional lymph nodes) or distant (cancer has metastasized) stages were categorized as 
‘late stage’. 
Aim 2 Main Exposure and Covariates 
 As with aim 1, there were three main exposures: distance travel to the screening 
provider, distance travel to the diagnosing mammography facility, and distance travel to 
the nearest mammography facility. Confounders and effect modifiers included age, race, 
income at time of enrollment, insurance status at time visit with the BCN, and marital 
status. Race was categorized as EA and AA.  Income at time of enrollment was 
categorized into three groups: <$10000, $10000-$19999, and >$20000. Health insurance 
status was categorized as Yes and No. Marital status was categorized into five groups: 







GIS Approach and Statistics Methods 
As with aim one, distance calculations and goecoding were done on-site at SC 
DHEC. A de-identified dataset was exported to SAS for analyses. Descriptive statistics 
were performed for all characteristic variables. Chi-square test and t-test were used to test 
for differences between demographic and race variables. Chi-square was also used to 
compare breast cancer stage at diagnosis between BCN and non-BCN women. 
Multivariable logistic regression was used to assess the association between travel 
distance (to the screening provider, diagnosing mammography facility, and closest 
mammography facility) and stage of breast cancer at diagnosis. To assess whether travel 
distance was influenced by race, an interaction term was created between travel distance 
and race in each of the model (travel distance to screening provider-race, travel distance 
to diagnosing mammography facility-race, and travel distance to closest mammography 
facility-race). All distances to the health facilities were broken into < 5 miles, 5-<10 
miles, 10-<15 miles, and 15+ miles for statistical analysis. All analyses were performed 
using SAS version 9.3 (Cary, NC). A two-sided alpha level of 0.05 was used to determine 
significance for all tests.  
Aim 3: Evaluate the role of distance to the screening provider, nearest 
mammography facility, and mortality among women in the BCN. 
Research Question 3:  Does living further from the screening provider and closest 
mammography facility increase the risk of breast cancer mortality? Also, is there a 
difference by race/ethnicity? 
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For aim 3, the dataset source was the same dataset as in aim 2 (linkage between 
SCCCR and BCN).  
Inclusion Criteria for Aim 3  
Women included in the dataset include:  
 Is a first primary breast cancer case in SCCCR between 1996 and 2009 
 Known year of diagnosis  
 Known screening provider 
 Enrolled in BCN between 1996 and 2009 
 Residence address is not a PO Box address 
Aim 3 Outcome of Interest 
The outcome of interest was breast cancer-specific and all-cause mortality. To 
determine breast cancer-specific mortality, we looked at the “Sequence Number” and the 
“Cause of Death” from the cancer registry data. If the “Sequence Number” was “00”, 
meaning that the subject had one malignant primary in her lifetime, and the “Cause of 
Death” was “Cancer”, then the death was related to breast cancer.  If the subject died of 
any cause of death, including breast cancer, then the death was considered all-cause 
mortality.  
Aim 3 Main Exposure and Covariates 
 For aim 3, there were three main exposures: distance travel to the screening 
provider, distance travel to the nearest mammography facility, and distance travel to the 
diagnosing mammography facility. Patients’ characteristics were obtained from the BCN 
  
62 
and SCCCR, which included age, race, breast cancer stage, estrogen receptor status, 
marital status, health insurance, income, and first course of treatment. Breast cancer stage 
at diagnosis was categorized as in-situ, localized, regional, and distant. Estrogen receptor 
(ER) status was categorized as positive, negative, and borderline. Income at time of 
enrollment was categorized into three groups: <$10000, $10000-$19999, and >$20000. 
Health insurance status was categorized as Yes or No. Marital status was categorized into 
married or not married. Cancer treatments were categorized as surgery, radiation, 
chemotherapy, hormonal therapy, and none.  
Data Analysis 
GIS Approach and Statistics Methods 
 As with aims 1 and 2, geocoding and distance calculations were done on-site at 
SC DHEC and only a de-identified dataset was given to the researcher for analyses. 
Descriptive statistics were calculated for all characteristics variables. Chi-square tests and 
t-tests were used to examine the associations between characteristics variables and race. 
Survival probabilities for breast cancer-specific and all-cause mortality were examined 
using Kaplan-Meier survival method. Cox proportional hazard modeling was used to 
assess the relationship between mortality and travel distance to the screening referral 
provider, diagnosing mammography facility, and closest mammography facility. To 
assess whether travel distance was influenced by race, we created an interaction term 
between travel distance and race in each of the Cox proportional hazard model (travel 
distance to screening provider-race, travel distance to diagnosing mammography facility-
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race, and travel distance to closest mammography facility-race). Due to low sample size, 
all distances were categorized into <10 miles and 10+ miles for analysis. 
Individuals not found to be deceased at the end of the time period, December 31, 
2009, were considered to be alive at the time of censoring. For breast cancer specific 
mortality, non-cancer cause of death and cancer death other than breast cancer were also 
considered censored. The proportional hazards assumption was examined through the 
logarithm of negative logarithm of survival probability with logarithm of time and the 
Schoenfeld residuals were further evaluated to confirm that there were no violations of 
the assumption. Missing data were excluded from analyses. All analyses were done using 
SAS statistical software version 9.3 (Cary, NC). All statistical tests were 2-sided with a 
P-value of ≤ 0.05 used to determine statistical significance.  
Summary 
 This study used 14 years of data (1996-2009) to investigate the relationship 
between three types of travel distances (to the screening provider, diagnosing 
mammography facility, and closest mammography) and completion of abnormal 
mammography follow-up, breast cancer stage at diagnosis, and mortality among women 
participating in South Carolina’s Best Chance Network. Data source for aim one came 
from BCN and for aims two and three, the data source came from a linkage between 
SCCCR and BCN. Geocoding and distance calculations were performed on-site at the SC 
DHEC. Only a de-identified dataset was released from DHEC for analyses.  All data 





1. Henson RM, Wyatt SW, Lee NC. The National Breast and Cervical Cancer Early 
Detection Program: a comprehensive public health response to two major health 
issues for women. J Public Health Manag Pract. 1996;2:36-47. 
 
2. National Breast and Cervical Cancer Early Detection Program (NBCCEDP). 
South Carolina: Five-Year Summary: July 2005 to June 2010. 
(http://www.cdc.gov/cancer/nbccedp/data/summaries/south_carolina.htm). 
(Accessed October 20, 2011).  
 
3. American College of Radiology. BI-RADS mammography. 
(http://www.acr.org/secondarymainmenucategories/quality_safety/biradsatlas/bira
dsfaqs.aspx). (Accessed August 25, 2011).  
 
4. South Carolina Department of Health and Environmental Control: South Carolina 
Central Cancer Registry. 
(http://www.scdhec.gov/co/phsis/biostatistics/SCCCR/AboutARegistry.htm). 






TRAVEL DISTANCE TO SCREENING FACILITIES AND COMPLETION OF ABNORMAL 












                                                             
1
 Khang, L., S.A. Adams, S.E. Steck, J. Zhang, S. Xirasagar, D. Lydiard. To be submitted 




Introduction: Breast cancer is the most common cancer diagnosed and is the second 
leading cause of cancer deaths among women in South Carolina. Annual mammography, 
with timely and complete follow-up of abnormal mammogram, improves breast cancer 
prognosis and survival. Though many studies have examined factors in predicting 
incomplete and delay in abnormal mammogram follow-up, none has used geospatial 
methods to examine these factors. Consequently, the purpose of this study was to 
examine the relationship between travel distance to the screening provider, 
mammography facility, and completion of abnormal mammogram follow-up among 
disadvantaged women in South Carolina. Methods: Women participating in South 
Carolina’s Best Chance Network between 1996 and 2009 with abnormal mammogram 
(BI-RADS category of 4 or 5) were included in the study. Racial differences in 
characteristics and completion of abnormal mammogram follow-up were tested using 
chi-square and t-tests. Kaplan-Meier survival method was used to compute time to 
completion of abnormal mammogram follow-up and Cox proportional hazard modeling 
was used to assess the relationship between work-up completion and travel distance to 
screening provider and mammography facility. Results: Among 1,388 women with 
mammography abnormalities, more than 95% achieved completion in follow-up. There 
was no significant association between race and overall completion of abnormal 
mammogram work-up. However, there was significant difference in time to completion 
of abnormal mammogram work-up and race; African American women had longer time 
to completion compared to European American women. Accounting for race, age, 
previous mammograms, income, and insurance status, women who lived closest to their 
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diagnosing mammography facility were more likely to complete their work-up compared 
to those who lived the farthest  (HR=1.41; 95% CI=1.00-1.80). Conclusion: There is no 
racial disparity in the overall completion of abnormal mammogram follow-up among 
women in the Best Chance Network. However, distance to the diagnosing mammography 
facility plays a role on the completion of abnormal mammogram work-up and days to 
completion of the work-up, which was longer for African American women.  
Introduction 
 Breast cancer is the most commonly diagnosed cancer and is the second cause of 
cancer-related mortality among women in the United States (1). Mammography is the 
single most effective method of early detection of breast cancer; it can identify the cancer 
at an early stage, when treatment is more effective (2). The American Cancer Society 
screening guidelines recommend that average-risk women aged 40 and older receive 
mammography screening on an annual basis (1). Annual mammography with adequate 
follow-up is estimated to result in reductions in mortality ranging from 25% to 44% (3-
7). Despite the benefit of mammography, many women are not up-to-date on screening 
(8-10) and about 38%-54% do not maintain annual adherence to screening mammograms 
(8, 9). Inadequate screening and follow-up are associated with late stage breast cancer at 
diagnosis (10-14), which lead to poor survival.  
 About 9%-15% of women who receive mammography screening have an 
abnormal finding that require further testing (15, 16), and approximately 30%-50% will 
delay follow-up testing (17, 18). Women who delay follow-up testing increase the risk of 
having larger tumor size, late-stage breast cancer at diagnosis, and poorer prognosis.  
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Factors contributing to inadequate or incomplete abnormal mammogram follow-up 
include: fear (19), language barrier (20), race/ethnicity (21-25), lack of provider (25), 
income level (24, 26), and education (27). 
 South Carolina is a relatively rural state with approximately 30% African 
American representation (28). The poverty rate in South Carolina from 2008-2009 is 
about 20%, with African Americans having a higher rate compared to European 
Americans (35% vs. 13%, respectively) (28). At close to 18% (29), South Carolina has 
one of the highest proportions of uninsured women in the nation. Breast cancer is the 3
rd
 
most common cancer diagnosed and is the second leading cause of cancer deaths among 
women in South Carolina (30).  
To reduce the disproportionate burden of breast cancer and ensure adequate 
follow-up from abnormal mammograms among disadvantaged women in South Carolina, 
the Best Chance Network (BCN), which is the state program of the National Breast and 
Cervical Cancer Early Detection Program (NBCCEDP) was established in 1991. The 
program has established service delivery and ensures timely and complete diagnostic 
follow-up and treatment initiation for underserved women screened through the program. 
Though many studies have examined factors in predicting incomplete and delay in 
abnormal mammogram follow-up (19-27), none have used geospatial methods to 
examine factors related to distance to screening facilities. The purpose of this study was 
to examine the relationship between travel distance to the screening provider, diagnosing 
mammography facility, closest mammography facility, and completion of abnormal 





 Study participants were women from the Best Chance Network of South Carolina. 
The program provides free mammograms, clinical breast exams, Pap tests, pelvic exams, 
diagnostic procedures, case management, community education on breast/cervical cancer 
and early detection for underserved women aged 47-64 years, who are at or below 200% 
of the Federal trade poverty level, and those who lack insurance or have insurance that 
only covers hospital care. BCN is a network that consists of public and private 
partnerships between federally-funded primary care centers, private physicians, 
laboratories, university sponsored clinics, free clinics, regional medical centers, and 
radiology facilities. In the last five years (January 2007-December 2011), the BCN has 
performed 24,917 mammograms to eligible women in the state (31). .   
Mammogram results are interpreted by radiologists using the American College 
of Radiologist Breast Imaging Reporting and Data System (BIRADS
TM
) categories: 0 – 
“incomplete”; 1-“Negative”; 2-“Probably benign”; 3-“Suspicious”; 4-“Suspicious 
abnormality”; 5-Highly suspicious of malignancy”; and 6-“Known biopsy proven 
malignancy” (32).  A category of 4 and 5 requires additional diagnostic procedures to 
determine the presence or absence of the disease. All participants with abnormal 
mammography are provided with case management services, which work with the 
participant to help her receive follow-up diagnostic services within 60 days.   
Subjects were included in the analyses if they were enrolled in BCN between 
1996 and 2009 and had an abnormal mammogram BI-RADS reading (BI-RADS category 
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of 4 or 5). Only women with race/ethnicity categorized as African American (AA) and 
European American (EA) were included in the sample because other individual racial or 
ethnic groups (n=31) did not have sufficient numbers to make meaningful contributions 
to the analysis. A total of 1,392 BCN participants were obtained from BCN. 
The study was approved by the South Carolina’s Department of Health and 
Environmental Control (SC-DHEC) and was exempted from approval from the 
Institutional Review Board of the University of South Carolina Office of Research. 
Measures 
 The outcome of interest was time-to-resolution or completion of abnormal 
mammogram follow-up. The measure of time was the number of days between the first 
mammogram and the date that the follow-up status was finalized (work-up completed, 
refused, or lost-to-follow up). A completed work-up is designated when the diagnostic 
testing is complete and a final diagnosis has been made (benign or malignant breast 
cancer). Refused work-up indicates a woman had her diagnostic work-up performed by 
another provider. A loss-to-follow up status indicates that the woman died, moved before 
her work-up started, or BCN could not make contact with the patient.  
 There were three main exposure variables of interest: travel distance to the 
screening provider, travel distance to the diagnosing mammogram facility, and travel 
distance to the nearest mammography facility. The travel distances were calculated in 
miles and along the road network based on point location of residence to the facilities 
using ArcGIS 9.3 (Redland, CA) Network Analyst.  Geocoding of residence and facilities 
were done using the Method and Tiers method (33) developed by the SC-DHEC. 
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Patients’ addresses, screening providers’ addresses, and diagnosing mammography 
facilities’ addresses were obtained from BCN. The closest mammography facilities were 
identified from a regularly updated list of Food and Drug Administration (FDA) 
accredited facilities (34). Of the 1,392 subjects, we excluded 4 subjects because they 
were out of state. We also excluded all patients and screening providers with missing 
addresses, addresses that were PO Boxes and those that were matched to the 5-digit zip 
code only.  There were 1,073 subjects left with matchable addresses. There were 218 
screening providers; however, we were able to geocode only 137 facilities due to missing 
addresses and PO Boxes. There were 500 patients with a diagnosing mammography 
facility designated.  Due to change in data collection, a portion of the records only 
captured the provider where the initial referral or screening mammography was 
performed.  Thus, we were unable to perform geospatial analyses using diagnosing 
facility for these individuals. There were a total of 111 certified mammography facilities, 
identified from the FDA list, in South Carolina that were used as the closest 
mammography facilities. All distances to the screening provider, diagnosing 
mammography facilities, and closest mammography facilities were broken into < 5 miles, 
5-<10 miles, 10-<15 miles, and 15 + miles. Demographic characteristics obtained from 
BCN for analyses included age, race, previous mammogram, yearly family income, and 
insurance status at time of visit with the BCN.  
Statistical Analysis 
 Descriptive statistics were calculated for all characteristic variables. Chi-square 
test and t-test were used to examine the bivariate associations between demographic and 
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race variables. The median days and distances from the abnormal mammogram to 
diagnostic resolution were assessed with Kaplan-Meier survival method. Wilcoxon test of 
equality over strata was used to test for statistical significant between the distances.  
 Cox proportional hazard modeling was used to assess the relationship between 
work-up completion and travel distance to the screening provider and mammography 
facility.  Women whose final status was recorded as refused or loss-to-follow up were 
considered censored observations. The proportional hazards assumption was examined 
through the logarithm of negative logarithm of survival probability with logarithm of 
time and the Schoenfeld residuals were further evaluated to confirm that there were no 
violations of the assumption. All analyses were performed using SAS version 9.3 (Cary, 
NC). A two-sided alpha level of 0.05 was used to determine significant for all tests.  
Results 
 A total of 1,073 women were identified through the BCN. The mean age for AA 
and EA women was 54.4 (SD=7.01) and 53.8 (SD=7.79), respectively. There was no 
statistically significant difference in the mean age between the two race groups (p=0.15). 
EA women had higher income than AA women (p<0.01). There was statistically 
significant difference for travel distance to the screening provider among AA and EA 
women, with EA women having longer travel distance (p<0.01). For both groups of 
women, more than 95% had completed follow-up of abnormal mammogram. There was 
no statistically significant difference in insurance status, previous mammograms, and BI-
RADs reading among the groups of women.  The study population characteristics are 
displayed in Table 4.1.   
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 The median day to resolution with travel distances are displayed in Table 4.2. The 
median day to resolution for travel distance to the screening provider, diagnosing 
mammography facility, and closest mammography facility were within 3 days of each 
other (22 days, 23 days, and 25 days, respectively). There was no significant difference 
between the travel distance to the screening provider and time to resolution. However, 
there was significant difference between travel distance to the diagnosing mammography 
facility and time to resolution. Women who lived farther from their diagnosing 
mammography facility had longer median day to resolution. Figures 4.1-4.3 present the 
estimated Kaplan Meier survival curves for travel distance to the health facilities and 
time to resolution. 
  The median days to resolution, stratified by race, are displayed in Table 4.3. For 
travel distance to the screening provider, diagnosing mammography facility, and closest 
mammography facility, AA women had significantly longer days to resolution compared 
to EA women. The largest difference in time to resolution was in travel distance to the 
diagnosing mammography facility (28 days for AA women vs. 22 days for EA women). 
Figures 4.4-4.6 present the estimated Kaplan Meier survival curves for travel distance to 
the health facilities and time to resolution, by race. 
 Table 4.4 presents the Cox proportional hazard analysis by travel distance to each 
of the facilities. Accounting for race, age, previous mammograms, income, and insurance 
status, women who lived closest (< 5 miles) to the diagnosing mammography facility 
were more likely to complete their work-up compared to those who lived the farthest (15 
+ miles) (HR=1.41; 95% CI=1.00-1.80). Though the interaction between travel distance 
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and race was not statistically significant, we further analyzed by race because it was 
integral to our post-hoc hypothesis. When stratified by race, AA women who lived the 
closest to their diagnosing mammography facility were 1.39 times more likely to 
complete the recommended work-up compared to AA women who lived the farthest from 
their diagnosing mammography (Table 4.5).  
Discussion 
 To our knowledge this is the first study to use geospatial method to examined 
travel distance and completion of abnormal mammography follow-up among a 
population of women with homogeneous socioeconomic status. In this analysis of women 
participating in South Carolina’s Best Chance Network, we found that geographical 
location of the health facility plays a role in the completion of work-up following an 
abnormal mammographic finding. Women who lived the closest to their diagnosing 
mammography facility were more likely to have a completed abnormal mammogram 
follow-up compared to those who lived the farthest. Similar to other studies, we found 
race was not significantly associated with overall completion of mammographic work-up 
(22, 24, 35-36). However, in all travel distances, AA women had longer days to 
completion of abnormal mammogram work-up compared to EA women. Among travel 
distance to the diagnosing and closest mammography facilities, women who lived the 
farthest had longer median days to resolution compared to those who lived the closest.  
We performed a sensitivity analysis using travel distance to the diagnosing 
mammography and compared with travel distance to the closet mammography facility. 
Interestingly, we observed no association between completion of abnormal mammogram 
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follow-up and travel distance to the closest mammography facility, but we did observe an 
association with travel distance to the diagnosing mammography facility. Women were 
more likely to have their abnormal mammogram follow-up completed if they were living 
closest to their diagnosing mammography facility. There may be reasons why we see this 
unparalleled result. As of 2011, there were 111 certified mammography facilities 
(excluding mobile facilities) in South Carolina. We used this updated list of certified 
mammography facilities to calculate distance to the closest mammography facility. 
Several of these facilities may have been added in recent years and calculating the 
distance between these facilities and the patient’s residence may not be the actual closest 
mammography facility utilized. By using this list, we are assuming that women received 
service at a facility closest to home and that all facilities were in existence at the 
beginning of the study (1996). Selection of a facility for service depends on many criteria 
and may not always be the closest to home. Hence, inaccuracy of travel distance to the 
closest mammography center can occur. This sensitivity analysis showed that by using 
the closest mammography facility instead of the actual utilized mammography facility, 
we may bias our findings toward to null. 
 There are several limitations to this investigation that are worth noting. First, the 
BCN program collects minimal data elements; therefore, we did not have information on 
the patient-provider relationship, or patients’ behaviors and beliefs about breast cancer 
screening. This information would be useful in determining the reasons for some of our 
findings. Misclassification for the variable ‘status of mammogram at final diagnosis’ can 
bias our finding. When grouping ‘refused’ and ‘loss to follow-up’ into incomplete work-
up, we may have introduced misclassification bias if the factors associated with them are 
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different from each other. Nevertheless, our analyses (data not shown) showed that there 
were no significant differences between the mean travel distance between those in the 
‘refused’ and ‘loss to follow-up’ groups.  Exclusion of women for various reasons can 
also bias our findings. In this investigation, 315 women were excluded due to PO Box 
addresses or not geocodeable to the exact street level. If the characteristics of these 
women differ from those with geocodeable addresses, our results may be biased. We 
found no significant differences between insurance status, BI-RADS reading, and the 
status of mammography at final diagnosis among the geocodeable and non-geocodeable 
groups; hence, excluding women with non-geocodeable addresses is unlikely to bias our 
estimates. 
Our main exposure was travel distance. Though women in the study were 
geocoded to the exact street address, the geocoded address may not be the actual location 
of residence. This can happen due to new developments, rural areas or streets that are not 
captured by the geocoding map. Therefore, when calculating the distance from residence 
to the providers and mammography facilities, we may be under or over-estimating the 
true distance of travel. How much this biases our findings is unknown.  
 Though we used road network to measure the distance from patient’s residence to 
the screening provider and mammography facility, we had no information on other 
factors that can affect utilization such as car ownership or reliability of public 
transportation. The type of transportation a patient uses can affect whether a patient will 
go to the health center or not. It has been shown that transportation is an important factor 
and is associated with mammography receipt (37).   
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 The major strength of this analysis is that we derived travel distance from the 
exact street address of a patient’s residence to the screening provider and mammography 
facility. This method gives us a more precise measurement of travel distance compared to 
other method that has been used in computing travel distance, which uses the five-zip 
code centroid.   
 In addition, we were able to compute distance to the diagnosing mammography 
facility. Healthcare can sometime be a choice and patient may not always utilize the 
closest health facility due to various reasons. By using the actual diagnosing 
mammography facility to compute the distance from the patient’s residence, we have a 
good estimate of the actual travel distance. From our analysis, we found an association 
between travel distance to diagnosing mammography facility and completion of abnormal 
mammogram follow-up, but not for the closest mammography facility. 
 In conclusion, we found no racial disparity in the overall completion of abnormal 
mammogram work-up among AA and EA women participating in the BCN program and 
approximately 86% of the women had their work-up completed within 60 days. This 
suggests that the program is meeting established program standards of timeliness and 
completeness of follow-up for women with abnormal mammographic finding. However, 
we did found that geographical location of the diagnosing mammography facility plays a 
role in the days to completion of work-up. Women living closest to their diagnosing 
mammography facility were more likely to complete the work-up and have shorter days 
to completion compared to those who lived the farthest.  In addition, we found evidence 
of racial disparity in the time to completion of abnormal mammogram work-up; AA 
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women had longer days to completion compared with EA women. These finding reveals 
that geographic accessibility to mammography facility may have an impact on 
completion of abnormal mammogram work-up and days to completion of the work-up. 
Intervention strategies and additional support to the BCN program to expand services 
should be investigated to reduce the disparity in days to completion of abnormal 
mammographic finding among racial ethnic groups. Further research that examines 
factors which affect geographic access, such as ownership of reliable transportation and 
access to public transportation, may further our understanding.    
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Table 4.1. Demographic Characteristics of the Study Population, by Race* 
 Black (n=591) White (n=482)  





Age    
      <40 years 7 (1.2%) 13 (2.7%) 0.19 
     40-49 years 149 (25.2%) 135 (28.0%)  
     50-64 years 416 (70.4%) 320 (66.4%)  
     65 + years 19 (3.2%) 14 (2.9%)  
Previous Mammography    
     Yes 258 (43.7%) 220 (45.8%) 0.79 
     No 254 (43.1%) 199 (41.5%)  
     Unknown 78 (13.2%) 61 (12.7%)  
BI-RADS    
     BI-RADS 5 (highly    
        suggestive malignancy) 
133 (22.5%) 107 (22.2%) 0.91 
     BI-RADS 4 (suspicious  
        abnormality) 
458 (77.5%) 375 (77.8%)  
Insurance    
     Yes 56 (9.5%) 43 (9.0%) 0.52 
     No 535 (90.5%) 438 (90.9%)  
Income    
     <$10,000 428 (72.4%) 284 (58.9%) <0.01 
     $10,000-$19,999 145 (24.5%) 166 (34.4%)  
     >$20,000 18 (3.1%) 32 (6.6%)  
Travel Distance    
     Provider  371 (10.0±10.5) 313 (13.6±16.5) <0.01 
     Diagnosing  
        mammography facility 
292 (15.1±15.2) 208 (16.2±17.3) 0.43 
     Nearest mammography  
        facility 
591 (7.9±6.9) 482 (7.9±5.9) 0.95 
Status of Mammography at 
Final Diagnosis 
   
     Work-up complete 562 (95.1%) 462 (95.9%) 0.55 
     Work-up not complete 29 (4.9%) 20 (4.2%)  





Table 4.2. Median days to Diagnostic Resolution among Women in BCN with 
Abnormal Mammogram*, by Travel Distance 
Distance n Median Days to Resolution 
(Range)** 
P-value*** 
Distance to Provider    
     < 5 miles 212 22 (18-26) 0.99 
     5 - < 10 miles 151 21 (19-27)  
     10 - < 15 miles 108 22 (20-28)  
     15 + miles 173 23 (19-27)  
Total 644 22 (21-24)  
Distance to Diagnosing 
Mammography 
   
     < 5 miles 120 22 (19-25) 0.05 
     5 - < 10 miles 103 21 (18-29)  
     10 - < 15 miles 66 26 (20-33)  
     15 + miles 182 29 (24-35)  
Total 471 23 (21-27)  
Distance to Closest 
Mammography 
   
     < 5 miles 464 26 (23-28) 0.87 
     5 - < 10 miles 250 23 (21-28)  
     10 - < 15 miles 139 24 (19-29)  
     15 + miles 161 27 (21-29)  
Total 1,014 25 (23-27)  
*Bi-RADS results of 4 (suspicious abnormality) or 5 (highly suggestive of 
malignancy)  
** Median days are from Kaplan-Meier estimates  






Table 4.3. Median days to Diagnostic Resolution among Women in BCN with Abnormal Mammogram*, by Travel 
Distance and Race 
 Black  White   
Distance n Median Days to 
Resolution 
(Range)** 




Distance to Provider        
     < 5 miles 147 23 (18-31) 0.79 65 21 (14-25) 0.79 <0.01 
     5 - < 10 miles 79 25 (19-29)  72 20.5 (14-23)   
     10 - < 15 miles 55 22 (19-29)  53 23 (18-31)   
     15 + miles 75 28 (21-37)  98 20.5 (16-24)   
Total 356 24 (21-28)  288 21 (18-23)   
Distance to Diagnosing 
Mammography 
       
     < 5 miles 89 22 (19-29) 0.09 31 21 (11-29) 0.36 <0.01 
     5 - < 10 miles 50 27 (15-31)  53 21 (18-29)   
     10 - < 15 miles 37 32 (21-40)  29 20 (13-26)   
     15 + miles 108 30 (25-40)  74 27 (20-35)   
Total 284 28 (24-31)  187 22 (20-26)   
Distance to Closest 
Mammography 
       
     < 5 miles 287 25 (22-31) 0.79 177 26 (21-28) 0.56 <0.01 
     5 - < 10 miles 110 29 (21-37)  140 21 (18-23)   
     10 - < 15 miles 73 26 (20-33)  66 19 (14-33)   
     15 + miles 98 28 (22-35)  63 20 (14-27)   
Total 568 27 (24-29)  446 22 (21-25)   
*Bi-RADS results of 4 (suspicious abnormality) or 5 (highly suggestive of malignancy)  
** Median days are from Kaplan-Meier estimates  
*** Wilcoxon Test of Equality over Strata 
**** Kaplan-Meier curves comparison of the number of days to resolution among black and white (Log-rank test) 
 
82 















    
     < 5 miles 14 209 0.94 (0.76-1.15) 1.04 (0.84-1.29) 
     5 - < 10 miles 4 161 1.04 (0.83-1.30) 1.05 (0.84-1.31) 
     10 - < 15 miles 5 109 1.06 (0.83-1.36) 1.08 (0.84-1.38) 




    
     < 5 miles 8 119 1.32 (1.04-1.67) 1.41 (1.00-1.80) 
     5 - < 10 miles 6 106 1.33 (1.04-1.70) 1.33 (1.03-1.72) 
     10 - < 15 miles 3 66 1.06 (0.80-1.42) 1.09 (0.81-1.45) 




    
     < 5 miles 24 466 1.03 (0.86-1.23) 1.03 (0.86-1.23) 
     5 - < 10 miles 10 253 1.12 (0.92-1.37) 1.06 (0.87-1.30) 
     10 - < 15 miles 10 137 0.97-0.77-1.22) 0.87 (0.69-1.10) 
     15 + miles 4 168 1.00 1.00 
*Adjusted for race, age, previous mammogram, income, insurance, and screening 
provider 






Table 4.5. Adjusted Hazard Ratio of Completion of Abnormal Mammography Work-up, by Race 
 Black White 


















        
     < 5 miles 12 140 0.94 (0.70-1.25) 1.03 (0.77-1.39) 2 69 1.18 (0.56-1.63) 1.19 (0.85-1.66) 
     5 - < 10 miles 2 80 1.08 (0.79-1.50) 1.13 (0.82-1.57) 2 81 1.04 (0.77-1.42) 0.94 (0.69-1.29) 
     10 - < 15 miles 2 56 1.27 (0.89-1.81) 1.29 (0.90-1.85) 3 53 0.91 (0.65-1.29) 0.89 (0.63-1.26) 




        
     < 5 miles 7 86 1.40 (1.04-1.87) 1.39 (1.03-1.88) 1 33 1.34 (0.87-2.05) 1.58 (1.01-2.48) 
     5 - < 10 miles 3 48 1.42 (1.00-2.01) 1.39 (0.97-1.99) 3 58 1.16 (0.82-1.66) 1.32 (0.91-1.92) 
     10 - < 15 miles 2 37 1.01 (0.69-1.48) 0.97 (0.65-1.44) 1 29 1.13 (0.73-1.76) 1.28 (0.81-2.02) 




        
     < 5 miles 17 281 1.06 (0.84-1.34) 1.06 (0.84-1.34) 7 185 0.95 (0.71-1.27) 0.97 (0.72-1.31) 
     5 - < 10 miles 5 109 1.05 (0.80-1.39) 0.99 (0.75-1.32) 5 144 1.09 (0.81-1.48) 1.09 (0.80-1.48) 
     10 - < 15 miles 5 70 0.99 (0.73-1.36) 0.91 (0.66-1.25) 5 67 0.90 (0.63-1.29) 0.83 (0.57-1.20) 
     15 + miles 2 102 1.00 1.00 3 66 1.00 1.00 
*Adjusted for race, age, previous mammogram, income, insurance, and screening provider  
HR=Hazard ratio; CI=95% confidence interval 
P-value interaction: Distance to provider*race = 0.20; p-value interaction: Distance to diagnosing mammography*race = 0.79; p-value interaction to 




































Figure 4.4: Days to Diagnostic Resolution, by Travel Distance to the Screening Provider and Race 
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Figure 4.5: Days to Diagnostic Resolution, by Travel Distance to the Diagnosing Mammography Facility and Race 
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Figure 4.6: Days to Diagnostic Resolution, by Travel Distance to the Closest Mammography Facility and Race 
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Introduction: South Carolina has some of the largest health disparities in the nation. 
Breast cancer is the most common cancer diagnosed and is the second largest cause of 
cancer deaths among women in the state.  Breast cancer stage at diagnosis is an important 
predictor of survival and mortality. In the past decades, researchers have explored 
geographic proximity to health care or mammography locations and breast cancer stage at 
diagnosis. However, findings have been inconsistent between the studies. The purpose of 
this study was to examine 1) whether travel distance to the screening provider and 
mammography facility are associated with stage of breast cancer at diagnosis among 
disadvantaged women who have screening available at no cost,  2) whether there are 
racial disparities in breast cancer stage at diagnosis among women in South Carolina’s 
Best Chance Network (BCN), and 3) whether there are any differences in the distribution 
of breast cancer stage at diagnosis among BCN participants and non-BCN participants. 
Methods: Women participating in South Carolina’s BCN between 1996 and 2009 with a 
first primary breast cancer and linked to the South Carolina Central Cancer Registry were 
included in the study. Racial differences in demographic characteristics and breast cancer 
stage at diagnosis were tested using chi-square and t-tests. Multivariable logistic 
regression was used to assess the association between travel distance and breast cancer 
stage at diagnosis. Results: Among 681 women with breast cancer, there was no 
statistically significant difference in the distribution of cancer stages by race (p=0.45). 
There was no strong evidence that longer travel distance to the screening provider and 
mammography facility was associated with late stage breast cancer at diagnosis among 




to non-BCN women Conclusion: There is no association between travel distance to the 
screening provider and mammography facility among economically homogenous women 
who have screening available at no cost. 
Introduction 
  Among women in the United States, breast cancer is the most commonly 
diagnosed cancer and is the second leading cause of cancer-related mortality (1). Using 
mammography for breast cancer screening is the single most effective method of early 
detection for breast cancer. Mammography can identify the cancer at an early stage, when 
survival rates are at their highest. Beginning at age 40, the American Cancer Society 
(ACS) recommends screening mammography on an annual basis for average-risk women 
(1). However, about 38-54% of women do not maintain annual adherence to screening 
mammograms (2, 3).  
Breast cancer stage at diagnosis is an important determinant of survival and 
mortality (4). Women with breast cancer diagnosed at advanced stage have limited 
treatment options and poorer survival compared to women with early stage breast cancer. 
The 5-year relative survival rates among women whose breast cancer is diagnosed while 
in the regional stage are nearly four times greater than those of women whose cancer has 
spread to distant (distant stage) lymph nodes or organs at the time of diagnosis (84% vs. 
23%) (4).   Studies consistently show that women with low-income, women having no 
insurance or being under-insured, and racial/ethnic minorities are more likely to be 




Spatial methods have been widely used in breast cancer research to understand 
some of the disparities in breast cancer morbidity and mortality (12-20).  A common 
spatial method that has been examined is spatial accessibility to healthcare facilities. 
Accessibility, such as long travel distance, can discourage women to seek routine 
preventive care or screening. In the past decades, researchers have explored geographic 
proximity to health care or mammography locations and breast cancer stage at diagnosis 
(12-20). However, findings have been inconsistent between the studies. The inconsistent 
results in the literature highlight the need for further research. 
South Carolina has some of the largest health disparities in the nation (1). Breast 
cancer is the most common cancer diagnosed and is the second largest cause of cancer 
deaths among women in South Carolina (21). Statewide, the age-adjusted incidence of 
breast cancer from 2004-2008 have remained stable at around 119 per 100,000 women 
(1), with a higher age-adjusted incidence among European American (EA) women 
compared to African American (AA) women (127.6 and 111.3 per 100,000 women, 
respectively) (22), yet higher mortality among AA women compared to EA women (21).   
To reduce the disproportionate burden of breast cancer death among 
disadvantaged women in South Carolina, the Best Chance Network (BCN), which is the 
state program of the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) was established in 1991. South Carolina has one of the highest proportions 
of uninsured women in the nation, of which majority of these women are eligible to 
enroll in the program. The majority (60%) of women in BCN are AA and reside in rural 




travel distance to health facilities and breast cancer stage at diagnosis among 
disadvantaged women who have screening available at no cost. Consequently, the 
purpose of this study was to 1) investigate whether travel distance to the screening 
provider and mammography facility are associated with breast cancer stage at diagnosis 
among women participating in South Carolina’s BCN, 2) examine whether there are 
racial disparities in the distribution of breast cancer stage at diagnosis among BCN 
participants, and 3) examine whether there are  any differences in the distribution of 
breast cancer stage at diagnosis among BCN participants and non-BCN participants? 
Methods 
Study Setting/Participants 
 Study participants were women enrolled in the BCN of South Carolina, who 
developed breast cancer between 1996 and 2009. These women were linked to the South 
Carolina Central Cancer Registry (SCCCR) using probabilistic matching techniques with 
Link Plus software. The cut-off value used for our probabilistic matching was 1.   Data 
from the BCN and SCCCR were linked by first name, last name, middle name (if 
provided), date of birth, address, and social security number (SSN). 
 The SCCCR is a population-based data system that collects cancer statistics in the 
state of South Carolina. From the last audit, the registry has a completeness rate of 96.9% 
and an accuracy rate of 96.4%, both of which exceeded the national standard of 95%. 
SCCCR also maintains a “Gold Certification” from the North American Association of 





 There were 707 women with first primary breast cancer from BCN that were 
matched to the SCCCR. Only women with race/ethnicity categorized as AA and EA were 
included in the sample because other individual racial or ethnic groups (n=17) did not 
have sufficient numbers to make meaningful contributions to the analysis. We also 
excluded 9 women with unknown breast cancer stage at diagnosis. A total of 681 women 
were included in the study. To compare breast cancer stage at diagnosis between BCN 
and non-BCN women, we identified 46,126 non-BCN women with breast cancer from 
SCCCR between 1996 and 2009. 
The study was approved by the South Carolina’s Department of Health and 
Environmental Control (SC-DHEC), South Carolina Central Cancer Registry, and was 
exempted from approval from the Institutional Review Board of the University of South 
Carolina Office of Research. 
Measures 
The outcome of interest was breast cancer stage at diagnosis. Using the 
Surveillance Epidemiology and End Results (SEER) Summary Staging guide (25), breast 
cancer stages were dichotomized into ‘early stage’ and ‘late stage’; In situ and localized 
(confined to primary site) stages were considered ‘early stage’ and regional (spread to 
regional lymph nodes) or distant (cancer has metastasized) stages were categorized as 
‘late stage’. Demographic characteristics obtained from BCN and SCCR for analyses 
included age, race, income at time of enrollment, insurance status at time visit with the 
BCN, and marital status. Race was categorized as EA and AA.  Income at time of 




Health insurance status was categorized as Yes and No. Marital status was categorized 
into five groups: single, married, separated/divorced, widowed, and unknown. 
Three measures of geographic accessibility to health centers were calculated 
(travel distance to the screening provider, travel distance to the diagnosing 
mammography facility, and travel distance to the nearest mammography facility). The 
travel distances were calculated in miles and along the road network based on point 
location of residence (at the time of diagnosis) to the facilities using ArcGIS 9.3 
(Redland, CA) Network Analyst.  The Method and Tiers method (26), developed by the 
SC-DHEC, was used to geocode residential addresses and health facilities. All addresses, 
including patients, screening providers, and diagnosing mammography facilities were 
obtained from BCN.  We excluded all addresses that were missing, were PO Boxes and 
those that were matched to the 5-digit zip code only. Of the 681 subjects women that 
matched to the SCCCR, we were able to geocode all of their addresses. There were 218 
screening providers identified from BCN; however, we were able to geocode only 137 
facilities due to missing addresses and PO Boxes. Due to change in data collection over 
the years, a portion of the records only captured the provider where the initial referral or 
screening mammography was performed. Thus, we were able to identify 314 patients 
with a diagnosing mammography facility designated.   
Mammography facilities identified from a regularly updated list of Food and Drug 







 Descriptive statistics were performed for all characteristic variables. Chi-square 
test and t-test were used to test for differences between demographic and race variables. 
Chi-square was also used to compare breast cancer stage at diagnosis between BCN and 
non-BCN women. Multivariable logistic regression was used to assess the association 
between travel distance (to the screening provider, diagnosing mammography facility, 
and closest mammography facility) and stage of breast cancer at diagnosis. To assess 
whether travel distance was influenced by race, we created an interaction term between 
travel distance and race in each of the model (travel distance to screening provider-race, 
travel distance to diagnosing mammography facility-race, and travel distance to closest 
mammography facility-race). All distances to the health facilities were broken into < 5 
miles, 5-<10 miles, 10-<15 miles, and 15+ miles for statistical analysis. All analyses were 
performed using SAS version 9.3 (Cary, NC). A two-sided alpha level of 0.05 was used 
to determine significance for all tests.  
Results 
 There were a total of 681 women with first primary breast cancer diagnosed in the 
study. The majority (~54%) of the women were AA. The mean age for AA and EA 
women was 55.6 (SD=6.4) and 55.3 (SD=6.6), respectively.  The distribution of cancer 
stage at diagnosis among all women was in situ (16.3%), localized (44.6%), regional 
(35.1%), and distant (4.0%). There was no statistically significant difference in the 
distribution of cancer stage at diagnosis by race (p=0.45). Interestingly, EA women had 




mammography facility (p<0.01 and p=0.05, respectively) compared to AA women. 
However, there was no difference in travel distance to the closest mammography facility 
between AA and EA. The study population characteristics are displayed in Table 5.1. 
 Table 5.2 displays the breast cancer stage at diagnosis among BCN women and 
non-BCN women in the state of South Carolina. Women in BCN had fewer in situ and 
localized breast cancer stages at diagnosis compared to non-BCN women. There was no 
statistically significant difference by race in the distribution of cancer stage at diagnosis 
among BCN women. However, there was a statistically significant difference between 
breast cancer stage at diagnosis and race among non-BCN women, with AA women 
having higher percentage of regional and distant breast cancer at diagnosis compared to 
EA women. 
 Table 5.3 presents the crude and adjusted odds ratios predicting late stage breast 
cancer at diagnosis. In both crude and adjusted analyses, we found no significant relation 
between travel distance to the screening provider, closest mammography facility and 
breast cancer stage at diagnosis. However, in the adjusted model, women living 5-<10 
miles from their diagnosing mammography facility were 2.25 times more likely to be 
diagnosed with late stage breast cancer compared to women living < 5miles from their 
diagnosing facility. When stratified by race, there were no associations between travel 
distance to the screening provider, diagnosing mammography facility, closest 







 The main purpose of this investigation was to examine whether travel distance 
to the screening provider and mammography facility were associated with stage of 
breast cancer at diagnosis. To our knowledge this is the first study to use geospatial 
methods to examine this relationship among disadvantaged women who have screening 
available at no cost. In this analysis of women participating in South Carolina’s BCN, we 
found no convincing evidence that longer travel distance to the screening provider, 
diagnosing mammography facility, and closest mammography facility were associated 
with late stage breast cancer at diagnosis.  
 Our findings, though not what might be expected, are in agreement with some 
other studies that found no association between travel time and breast cancer stage at 
diagnosis (12-17). The lack of an association in the present study may reflect the BCN 
context. BCN is a network of public and private partnerships with more than 250 health 
care providers offering screening and follow-up services to disadvantaged women in the 
state. South Carolina is a relatively rural state and one might expect longer travel distance 
to health facilities among its residents. However, with an extensive BCN network 
providing service throughout the state, we found the mean travel distance to the screening 
provider is 10.9 miles (SD=10.5), diagnosing mammography facility is 14.6 miles 
(SD=15.8), and closest mammography facility is 8.1 miles (SD=6.5). One study found 
that among individuals living in rural Upper Great Plains states of Montana, North 
Dakota, South Dakota, and Wyoming had an average travel distance of 17 miles to health 




mammography facilities, travel distance may not be a major issue in our population. It 
could also be that the program, with its financial access, is providing adequate service for 
those with geographic distance challenges. 
One important aspect of our study was that we were able to compare breast cancer 
stage at diagnosis among BCN women to non-BCN women in the State of South 
Carolina. Though BCN women had slightly greater number of late stage breast cancers 
compared to non-BCN women, we found no evidence of racial disparity in breast cancer 
stage at diagnosis among women in BCN. This is evidence that the program is meeting 
established program standards of reducing health disparities among racial/ethnic groups.  
 The results of this study should be interpreted with consideration of several 
limitations. First, BCN and SCCCR collect minimal data elements; therefore, we did not 
have information on important factors that may contribute to stage of diagnosis, such as 
family history, body mass index, and other comorbidities. Though we used road network 
to measure the distance from patient’s residence to the screening provider and 
mammography facility, we had no information on the mode of transportation. The type of 
transportation a patient uses can affect whether a patient will seek health care or not. It 
has been shown that transportation is an important factor in screening for breast cancer 
(29). A study in rural North Carolina found that individuals who had a driver’s license 
had twice as many health care visits compared to those who did not (30). Though women 
in our study were successfully geocoded to the exact street address, the geocoded address 
may not be the actual location of residence. This can happen due to new developments, 




improved as geocoding expands. Another limitation is that we excluded many of the 
women with non-geocodeable address. These women may reside in more rural areas and 
may have long travel distance to the health facilities or vice versa. How much this bias 
our finding is unknown. 
 There are many strengths to this investigation. The major strength is that we 
were able to calculate travel distance from the exact street address of the women’s 
residence to the screening facilities. This method allowed us to depict a more accurate 
measurement of travel distance. Though we found no relationship between travel 
distance to the health facilities and breast cancer stage at diagnosis, we were able to 
calculate travel distance to the diagnosing mammography facility. Women may not 
utilize the nearest facility due to personal and neighborhood characteristics, such as hours 
of operation, conveniently located, and location to work. Relying on the closest 
mammography facility may underestimate the true travel distance between patients’ 
residence and actual mammography usage if the closest facility is not the one being 
utilized. Another strength of our investigation is that when we investigate the 
association between travel distance to the health facilities and breast cancer stages at 
diagnosis, we were able to focused on a homogenous socioeconomic status women who 
have screening available at no cost. This allowed us in the design phase to eliminate some 
factors (e.g. income, health insurance status, and having a provider) which may impact 
breast cancer stage at diagnosis.  
 Previous research in this area has produced mixed results. The reasons for these 




metropolitan) and geography may play a role. Research methodology can also explain the 
contrary findings. There were differences in the methodology used in examining breast 
cancer stage and travel distance to mammography facility among previous studies (12-
20). Tarvo et al. used the mean distance to the closest five mammography facilities and 
found no association between travel distance and breast cancer stage at diagnosis (12). 
The study in Washington by Onega et al. measured travel time instead of travel distance 
and also found no relationship (16). Two studies used patient’s zip code centroid to 
calculated distance to the nearest mammography facility and found that women who lived 
further from the mammography facility were more likely to be diagnosed with late stage 
breast cancer (19, 20). 
 In summary, we found no convincing evidence that longer travel distance to the 
screening provider and mammography facility was associated with late stage breast 
cancer at diagnosis among women participating in South Carolina’s BCN.  Though 
women in BCN have significantly higher proportion of late stage of breast cancer at 
diagnosis compared to non-BCN women, there was no racial disparity in the distribution 
of breast cancer stage at diagnosis among BCN women.  Accurately capturing 
accessibility to health centers, including geography and transportation method, should be 





Table 5.1. Demographic Characteristics of the Study Population, by Race* 










Age  337 (55.6±6.4) 295 (55.3±6.6) 0.58 
Breast Cancer Stage at 
Diagnosis 
   
     In situ 67 (18.4%) 44 (13.9%) 0.45 
     Localized 160 (43.8%) 144 (45.6%)  
     Regional 125 (34.3%) 114 (36.1%)  
     Distant 13 (3.6%) 14 (4.4%)  
Marital Status    
     Single 91 (25.9%) 39 (13.0%) <0.01 
     Married 97 (27.6%) 116 (38.5%)  
     Separated/Divorced 70 (19.9%) 72 (23.9%)  
     Widowed 52 (14.8%) 41 (13.6%)  
     Unknown 41 (11.7%) 33 (11.0%)  
Previous 
Mammography 
   
     Yes 149 (40.9%) 145 (46.0%) 0.34 
     No 148 (40.7%) 122 (38.7%)  
     Unknown 67 (18.4%) 48 (15.2%)  
Insurance    
     Yes 87 (23.85%) 76 (24.1%) 0.93 
     No 278 (76.2%) 239 (75.9%)  
Income    
     <$10,000 250 (68.5%) 189 (59.8%) 0.03 
     $10,000-$19,999 101 (27.7%) 104 (32.9%)  
     >$20,000 14 (3.8%) 23 (7.3%)  
Travel Distance    
     Provider  245 (9.3±9.6) 230 (12.6±12.0) <0.01 
     Diagnosing  
        mammography   
        facility 
176 (13.0±14.1) 138 (16.6±17.5) 0.05 
     Nearest  
        mammography  
        facility 
365 (8.2±7.1) 316 (8.0±5.8) 0.64 











Table 5.2. Breast Cancer Stage Among BCN Women Compared to Women in the State of South Carolina, 1996-2009 




Total AA EA p
a









In situ 111 (16.3%) 67 (18.4%) 44 (13.9%) 0.45 8,131 (17.6%) 1,846 (17.6%) 6,187 (17.6%) <0.01 <0.01 0.19 <0.01 
Localized 304 (44.6%) 160 (43.8%) 144 (45.6%)  23,954 (51.9%) 4,660 (44.4%) 19,041 (54.2%)     
Regional 239 (35.1%) 125 (34.3%) 114 (36.1%)  12,172 (26.4%) 3,354 (31.9%) 8,695 (24.8%)     
Distant 27 (4.0%) 13 (3.6%) 14 (4.4%)  1,869 (4.1%) 650 (6.2%) 1,202 (3.4%)     
a 
P-value-comparison between AA and EA among BCN women 
b
 P-value-comparison between AA and EA among non-BCN women 
c 
P-value-comparison between BCN total women to non-BCN total women 
d 
P-value-comparison between BCN AA women to non-BCN AA women 
e




Table 5.3. Crude and Adjusted Odds Ratios Predicting Late Stage Breast Cancer 














    
     < 5 miles 102 62 Referent Referent 
     5 - < 10 miles 71 41 0.95 (0.58-1.56) 1.04 (0.60-1.79) 
     10 - < 15 miles 48 31 1.06 (0.61-1.84) 1.14 (0.61-2.13) 




    
     < 5 miles 59 30 Referent Referent 
     5 - < 10 miles 35 24 1.35 (0.68-2.66) 1.30 (0.62-2.73) 
     10 - < 15 miles 28 27 1.90 (0.95-3.77) 2.25 (1.04-4.83) 




    
     < 5 miles 187 112 Referent Referent 
     5 - < 10 miles 105 60 0.95 (0.64-1.42) 0.91 (0.59-1.40) 
     10 - < 15 miles 63 44 1.17 (0.74-1.83) 1.13 (0.68-1.88) 
     15 + miles 60 50 1.39 (0.89-2.17) 1.50 (0.94-2.41) 









Table 5.4. Crude and Adjusted Odds Ratios Predicting Late Stage Breast Cancer at Diagnosis among Women in BCN, by Race 
 Black White 






















        
     < 5 miles 66 42 Referent Referent 36 20 Referent Referent 
     5 - < 10 miles 31 23 1.17 (0.60-2.26) 1.28 (0.61-2.70) 40 18 0.81 (0.37-1.77) 0.70 (0.30-1.64) 
     10 - < 15 miles 24 11 0.72 (0.32-1.62) 0.55 (0.20-1.49) 24 20 1.50 (0.67-3.36) 1.69 (0.69-4.11) 




        
     < 5 miles 42 20 Referent Referent 17 10 Referent Referent 
     5 - < 10 miles 16 12 1.58 (0.63-3.95) 1.34 (0.48-3.79) 19 12 1.07 (0.37-3.11) 0.72 (0.21-2.45) 
     10 - < 15 miles 17 15 1.85 (0.77-4.45) 2.09 (0.75-5.84) 11 12 1.85 (0.59-5.75) 1.52 (0.42-5.49) 




        
     < 5 miles 108 65 Referent Referent 79 47 Referent Referent 
     5 - < 10 miles 53 18 0.56 (0.31-1.05) 0.60 (0.31-1.18) 52 42 1.36 (0.79-2.34) 1.16 (0.64-2.11) 
     10 - < 15 miles 33 23 1.16 (0.63-2.14) 1.07 (0.53-2.16) 30 21 1.18 (0.61-2.29) 1.08 (0.51-2.26) 
     15 + miles 33 32 1.61 (0.91-2.87) 1.72 (0.92-3.21) 27 18 1.12 (0.56-2.25) 1.02 (0.60-2.63) 
* Adjusted for age at diagnosis, race, income, insurance status, and marital status   
OR= Odds ratio; CI=Confidence interval 
P-value interaction: Distance to provider*race = 0.23; p-value interaction: Distance to diagnosing mammography*race = 0.56; p-value 
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  CHAPTER 6 
TRAVEL DISTANCE TO SCREENING REFERRAL PROVIDER, MAMMOGRAPHY 
FACILITY, AND BREAST CANCER MORTALITY AMONG WOMEN IN A STATE 
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Introduction: The death rates from breast cancer have declined in the past decades; 
however, disparities between racial/ethnic groups remain. South Carolina has some of the 
largest health disparities in the nation, particularly breast cancer morbidity and mortality. 
The Best Chance Network was established to reduce the burden of breast cancer among 
disadvantaged women in the state. Although much has been done to identify factors 
related to breast cancer mortality, little has been done to examine the influence of 
geographic accessibility to health facilities and breast cancer mortality. The purpose of 
this study was to investigate whether travel distance to the screening referral provider and 
mammography facility are associated with breast cancer-specific and all-cause mortality 
among women participating in South Carolina’s Best Chance Network. We also sought to 
contrast and compare by race breast cancer-specific and all-cause survival among BCN 
participants. Methods: Women in South Carolina’s Best Chance Network, who 
developed breast cancer between 1996 and 2009 and self-identified as either African 
American (AA) or European  American(EA) (n=690), were included in the study. Chi-
square and t-tests were used to determine racial differences in characteristics among the 
women. Kaplan-Meier survival methods were used to determine the breast cancer-
specific and all-cause survival probabilities. Cox proportional hazard modeling was used 
to assess the relationship between travel distance and mortality (breast cancer-specific 
and all-cause mortality). Results: There were no statistically significant differences in 
breast cancer-specific and all-cause survival proportions between AAs compared to EAs. 
Women with 10+ miles of travel distance to the diagnosing mammography facility had ~ 




the association was no longer statistically significant after adjustment for various 
prognostics characteristics. In the adjusted model, there was no association between 
travel distance to the health centers and mortality (breast cancer-specific and all-cause 
mortality) among EA and AA women. Conclusion: We found no racial disparity in 
breast cancer-specific and all-cause survival among economically disadvantaged women 
participating in BCN. There is little evidence that geographic accessibility to these health 
facilities influence breast cancer-specific and all-cause mortality among women in a 
homogenous socioeconomic status.  
Introduction 
  In 2012, the American Cancer Society estimates approximately 226,870 new 
cases and 39,920 deaths from breast cancer among women in the United States (1).  
Although the overall death rates for breast cancer have declined in the past decades, the 
mortality rates differ among racial/ethnic and age groups (1, 2). Even though European 
American (EA) women have higher breast cancer rates, African American (AA) women 
are more likely to die from the cancer (2).  
 Breast cancer is the second largest cause of cancer deaths among women in South 
Carolina (3). The age-adjusted mortality rate in South Carolina from 2004-2008 have 
remained stable at ~ 24.3 per 100,000 women (1), with AA women having higher age-
adjusted mortality rate compared to EA women (31.2 and 22.2 per 100,000 women, 
respectively) (2). To reduce breast cancer disparities in South Carolina, the Best Chance 
Network (BCN), which is the state program of the National Breast and Cervical Early 




mammograms, clinical breast exams, Pap tests, pelvic exams, diagnostic procedures, case 
management, community education on breast/cervical cancer and early detection for 
underserved women aged 47-64 years, who are at or below 200% of the Federal trade 
poverty level, and those who lack insurance or have insurance that only covers hospital 
care. 
 Studies have shown that breast cancer stage at diagnosis (4), age (5), race (2, 4), 
socioeconomic status (6), lifestyle (7-9), tumor characteristics (10-11), and reproductive 
factors (12-14) are associated with breast cancer mortality and survival. There have been 
several studies that examined travel distance to the mammography facility and breast 
cancer stage at diagnosis (15-23); however, little has been done to examine geographic 
accessibility to the screening referral provider, mammography facility, and its association 
with breast cancer mortality. Consequently, the objective of this study was to 1) 
investigate whether travel distance to the screening referral provider and mammography 
facility are associated with breast cancer-specific and all-cause mortality among women 
participating in South Carolina’s BCN, and  2) to contrast and compare by race breast 
cancer-specific and all-cause survival among BCN participants . These women are 
homogeneous in terms of their socioeconomic status and they all have access to free 










 The setting of this study was the Best Chance Network of South Carolina. The 
program is a network consisting of public and private partnerships between health clinics 
and radiology facilities to provide free mammograms, clinical breast exams, Pap tests, 
pelvic exams, diagnostic procedures, case management, community education on 
breast/cervical cancer and early detection for disadvantaged women (below 200% of the 
Federal trade poverty level and those who lack insurance coverage) in the state. From the 
BCN, women with breast cancer confirmed and linked to the South Carolina Cancer 
Registry (SCCCR) between 1996 and 2009 were included in the current analyses. 
Demographic information from women with breast cancer in BCN were linked to the 
SCCCR using probabilistic matching techniques by first name, last name, middle name 
(if provided), date of birth, address, and social security number (SSN). The cut-off score 
of 1 was used in Link Plus for the probabilistic matching. 
From 1996 to 2009, there were 707 women with a first primary breast cancer 
diagnosed from BCN that were matched to the SCCCR. Due to the small sample of other 
ethnic groups (n=17), only women with race/ethnicity African American (AA) and 
European American (EA) were included in the study, leaving a  total sample of 690 
women for inclusion in the study. The study was approved by the South Carolina’s 
Department of Health and Environmental Control (SC-DHEC), South Carolina Central 
Cancer Registry, and was exempted from approval from the Institutional Review Board 





Three travel distance variables were calculated: travel distance to the screening 
referral provider, travel distance to the diagnosing mammography facility, and travel 
distance to the nearest mammography facility. ArcGIS 9.3 (Redland, CA) Network 
Analyst was used to calculate the travel distance in miles along the road network based 
on point location of residence to the facilities. Patients’ addresses, screening referral 
providers’ addresses, and diagnosing mammography facilities’ addresses were obtained 
from BCN. The closest mammography facilities were identified from the Food and Drug 
Administration’s (FDA) list of accredited facilities (24). All addresses were geocoded 
using the Method and Tiers method (25) developed by the SC-DHEC Informatics 
Division.  
Residential addresses among all 690 women were successfully geocoded to the 
exact street address. For all of the 690 women, we were able to calculate distance to the 
closest mammography facilities. Only 481 women had a screening referral provider’s 
address and 319 women had a diagnosing mammography facility recorded. Hence, we 
were only able to calculate travel distance to the screening referral provider and 
diagnosing mammography facility for these women.  
Outcomes 
The outcome of interest was breast cancer-specific and all-cause mortality. To 
determine breast cancer-specific mortality, we looked at the “Sequence Number” and the 
“Cause of Death” from the cancer registry data. If the “Sequence Number” was “00”, 




Death” was “Cancer”, then the death was related to breast cancer.  If the subject died of 
any cause of death, including breast cancer, then the death was considered all-cause 
mortality.  
Covariates 
Patients’ characteristics were obtained from the BCN and SCCCR, which 
included age, race, breast cancer stage, estrogen receptor status, marital status, health 
insurance, income, and first course of treatment. Breast cancer stage at diagnosis was 
categorized as in-situ, localized, regional, and distant. Estrogen receptor (ER) status was 
categorized as positive, negative, and borderline. Income at time of enrollment was 
categorized into three groups: <$10000, $10000-$19999, and >$20000. Health insurance 
status was categorized as Yes or No. Marital status was categorized into married or not 
married. Cancer treatments were categorized as surgery, radiation, chemotherapy, 
hormonal therapy, and none.    
Statistical Analysis 
 Descriptive statistics were calculated for all characteristics variables. Chi-square 
tests and t-tests were used to examine the associations between characteristics variables 
and race. Survival probabilities for breast cancer-specific and all-cause mortality were 
examined using Kaplan-Meier survival method. Cox proportional hazard modeling was 
used to assess the relationship between mortality and travel distance to the screening 
referral provider, diagnosing mammography facility, and closest mammography facility. 
To assess whether travel distance was influenced by race, we created an interaction term 




distance to screening provider-race, travel distance to diagnosing mammography facility-
race, and travel distance to closest mammography facility-race). Travel distance was 
broken into <5 miles, 5-<10 miles, 10-<15 miles, and 15+ miles. However, due to low 
sample size in some categories, distances were grouped into <10 miles and 10+ miles for 
analysis. 
Individuals not found to be deceased at the end of the time period, December 31, 
2009, were considered to be alive at the time of censoring. For breast cancer specific 
mortality, non-cancer cause of death and cancer death other than breast cancer were also 
considered censored. The proportional hazards assumption was examined through the 
logarithm of negative logarithm of survival probability with logarithm of time and the 
Schoenfeld residuals were further evaluated to confirm that there were no violations of 
the assumption. Missing data were excluded from analyses. All analyses were done using 
SAS statistical software version 9.3 (Cary, NC). All statistical tests were 2-sided with a 
P-value of ≤ 0.05 used to determine statistical significance.  
Results 
 Our study samples consisted of slightly more AA women compared to EA women 
(53.6% vs 46.4%, respectively). The mean age of the women was ~ 55 years old 
(standard deviation [SD] =6.7). The average travel distance to the screening provider, 
diagnosing mammography facility, and closest mammography facility were 10.8 miles 
(SD=10.9 miles), 14.4 miles (SD=15.7 miles), and 8.1 miles (SD=6.5 miles), 
respectively. EA women had significantly longer travel distance to the screening provider 




cancer specific deaths and 133 all-cause deaths.   Table 6.1 presents the study population 
characteristics by race.  
Figure 6.1 and 6.2 display the survival proportions for breast cancer-specific and 
all-cause among AA and EA women.  There were no significant racial differences in the 
overall 5-year survival proportions for breast cancer-specific (~87% for EA women and 
~85% for AA women, P = 0.64) and all-cause mortality (~81% for EA women and ~80% 
for AA women, P = 0.90).  
 Table 6.2 presents the results of the Cox proportional hazards models for breast 
cancer-specific and all-cause mortality. There was no association between travel distance 
to the screening referral provider, diagnosing mammography facility, closest 
mammography facility and all-cause mortality. Women with 10+ miles of travel distance 
to the diagnosing mammography facility had ~ 2.3-fold excess risk of death from breast 
cancer compared to those with < 10 miles of travel distance (hazard ratio [HR], 2.32; 
95% confidence interval [CI], 1.12-4.80). However, after adjustment for age, race, ER 
status, marital status, income, insurance status, breast cancer stage at diagnosis, and 
treatment, the association was no longer statistically significant. Women with 10+ miles 
of travel distance to the closest mammography facility also had excess risk of death from 
breast cancer compared to those with < 10 miles of travel distance to the closest 
mammography facility (HR, 1.83; 95% CI, 1.21-2.77). The association was also not 
significant after adjustment for covariates. 
 Table 6.3 presents the Cox proportional hazard analyses for breast cancer-specific 




status, breast cancer at diagnosis, and treatment, there was no association between travel 
distance to the health centers and mortality (breast cancer-specific and all-cause 
mortality) among both race groups. However, in the crude model for breast cancer-
specific, both AA and EA women who lived 10+ miles from the closest mammography 
facility had an increased risk of death from breast cancer compared to those who lived < 
10 miles (HR=1.75 [95% CI=1.00-3.05 and HR=1.93 [95% CI=1.04- 3.60], respectively).   
 The Cox proportional hazard analyses for all-cause mortality, by race, are 
displayed in table 6.4. There was no association between travel distance to the screening 
referral provider, diagnosing mammography facility, closest mammography facility and 
all-cause mortality among EA and AA women. 
Discussion 
 The purpose of this study was to assess whether travel distance to the screening 
referral provider, diagnosing mammography facility, and closest mammography facility 
are associated with breast cancer mortality and all-cause mortality among women in the 
BCN of South Carolina. The overall breast cancer-specific 5-year survival rate among 
women in BCN was ~86%. We found no significant racial differences in the overall 5-
year survival rate for breast cancer-specific and all-cause mortality among EA and AA 
women. Interestingly, the breast cancer-specific survival rate among AA women (~85%) 
was much higher than the United States national average of ~77% (2).  
 We found no evidence that longer travel distance to the screening referral 
provider, diagnosing mammography facility, and closest mammography was associated 




women who lived 10+ miles from their diagnosing mammography facility and closest 
mammography facility had increased risk of breast cancer mortality compared to those 
who lived < 10 miles from the facility. However, the association diminished once we 
controlled for other characteristics.  The null finding was similar to a study in Northern 
England, which found no association between travel time to the general practitioners and 
breast cancer survival (26). This study looked at approximately 28,000 breast cancer 
cases from the Northern and Yorkshire Cancer Registry & Information Service 
(NYCRIS) and found that patients living further from the general practitioner were not 
associated with breast cancer survival. However, they found an inverse association with 
travel time to the hospital and breast cancer survival; women living further from the 
hospital had a better chance of breast cancer survival compared to those living the 
closest. Though the population of this study may not be comparable to those in the BCN, 
similar findings were observed.  
 The findings from this study are subject to several limitations. One limitation of 
this study is that we had limited data on potentially important covariates. BCN and 
SCCCR collect minimal data for reporting purpose and we have no information on some 
of the important factors (e.g. family history, body mass index, lifestyle, and other 
comorbidities) that contribute largely to breast cancer mortality and survival. We also 
have limited data on tumor characteristics, such as Her-2/neu expression and 
progesterone receptor status, which also affect breast cancer mortality. Another limitation 
is that we have no information on the mode of transportation that the women use to get 
services from these facilities. Studies have shown that the type of transportation can 




geocoded address may not be the actual location of residence. This can happen due to 
new developments, rural areas or streets that are not stored in the geocoding map. Due to 
the demographic of our sample, which are mostly low income and uninsured women, the 
findings may not be generalizeable to other populations. 
 Our study also has several strengths. To our knowledge, this is first study to 
investigate whether travel distance influence breast cancer-specific and all-cause 
mortality among disadvantaged women in a funded program, which aims at improving 
breast and cervical health disparities. Another strength of this study was that we were 
able to compute travel distance from the exact street address of the women’s residence to 
the health facilities, which is a more accurate measurement of travel distance compared to 
using straight line or eulicudean distance. An additional strength was we were able to 
estimate travel distance based on the actual use of the mammography facility by using 
patient’s diagnosing mammography facility and residence at time of diagnosis.  
 We found no racial disparities in breast cancer-specific and all-cause mortality 
among women in BCN. The findings in this study may be unique, because our population 
was from a program that was established to provide adequate screening and follow-up 
among women who enter the program; therefore, we see no racial disparities. These 
findings may reveal that the program is meeting established program standards of 
reducing health disparities among racial/ethnic groups.   
There was no association between travel distance to the screening referral 
provider, diagnosing mammography facility, closest mammography facility and all-cause 




expected, we were not surprised with these null findings because our previous study (not 
yet published) did not find any convincing evidence that travel distance to the screening 
referral provider and mammography facility was associated with breast cancer stage of 
diagnosis. If we had found that travel distance to these facilities was associated with 
breast cancer stages at diagnosis, then we would have expected to find an association. 
  In conclusion, these findings suggest that geographic accessibility to these health 
facilities (screening referral provider, diagnosing mammography facility, and closest 
mammography facility) may not be a mediator to breast cancer mortality and survival 
among women in programs like BCN. Further research should be conducted of similar 
programs like BCN and in other parts of the country to confirm these findings. The 
geography from where our population came from was relatively rural and may not be 
generalized. Future research that examines factors which may affect geographic 





* Missing were excluded; number may not add up to total  
Table 6.1. Demographic Characteristics of the Study Population, by Race* 
 Black (n=370) White (n=320)  
Characteristics n (mean±SD) n (mean±SD) p-value 
Age  370 (55.6±6.7) 320 (55.4±6.6) 0.75 
Travel Distance    
     Provider  248 (9.3±9.6) 233 (12.5±12.0) <0.01 
     Diagnosing  
        mammography facility 
179 (12.6±14.1) 140 (16.4±17.5) 0.05 
     Nearest mammography  
        facility 
370 (2.46±1.19) 320 (2.54±1.03) 0.36 
 n (%) n (%)  
All Cause of Deaths    
     Dead 70 (18.9%) 63 (19.7%) 0.80 
     Alive 300 (81.1%) 247 (80.3%)  
Breast Cancer Deaths    
     Dead 50 (13.5%) 40 (12.5%) 0.69 
     Alive 320 (86.5%) 280 (87.5%)  
Breast Cancer Stage at Diagnosis    
     In situ 67 (18.4%) 44 (13.9%) 0.45 
     Localized 160 (43.9%) 144 (45.6%)  
     Regional 125 (34.3%) 114 (36.1%)  
     Distant 13 (3.6%) 14 (4.4%)  
Behavior of Cancer    
     In-situ 67 (18.1%) 44 (13.8%) 0.12 
     Invasive 303 (81.9%) 276 (86.3%)  
Estrogen Receptor Status    
     Positive 115 (60.5%) 115 (74.2%) <0.01 
     Negative 75 (39.5%) 38 (24.5%)  
     Borderline 0 (0.0%) 2 (1.3%)  
Marital Status    
     Unmarried 
(single/separated/divorced) 
214 (68.2%) 153 (56.7%) <0.01 
     Married 100 (31.8%) 117 (43.3%)  
Insurance    
     Yes 87 (23.5%) 77 (24.1%) 0.85 
     No 283 (76.5%) 242 (75.9%)  
Income    
     <$10,000 254 (68.7%) 190 (59.4%) 0.02 
     $10,000-$19,999 102 (27.6%) 107 (33.4%)  
     >$20,000 14 (3.8%) 23 (7.2%)  
Treatment    
     Surgery only 91 (43.1%) 73 (42.9%) 0.02 
     Surgery, radiation      36 (17.1%) 35 (20.6%)  
     Surgery, radiation, chemotherapy 50 (23.7%) 21 (12.4%)  
     Surgery, radiation, chemotherapy, 
hormone 
18 (8.5%) 26 (15.3%)  
     Hormone only 0 (0.0%) 2 (1.2%)  



















Table 6.2. Crude and Adjusted Hazard Ratios for Breast Cancer-Specific and All-Cause Mortality among Travel Distance 10+ 
miles Compared with < 10 Miles 



















        
     < 10 miles 36 1116 Referent Referent 53 1158 Referent Referent 




        
     < 10 miles 10 647 Referent Referent 19 677 Referent Referent 




        
     < 10 miles 47 2129 Referent Referent 79 2228 Referent Referent 
    10 + miles 43 1045 1.83 (1.21-2.77) 2.14 (0.95-4.83) 54 1101 1.38 (0.98-1.96) 1.81 (0.89-3.69) 
* Adjusted for race, age, estrogen receptor, marital status, income, insurance, treatment, and breast cancer stage at diagnosis 








Table 6.3. Crude and Adjusted Hazard Ratios for Breast Cancer-Specific Mortality among Travel Distance 10+ miles 
Compared with < 10 Miles, by Race 



















        
     < 10 miles 25 596 Referent Referent 11 520 Referent Referent 
    10 + miles 9 394 0.59 (0.27-1.26) 3.32 (0.42-
26.04) 




        
     < 10 miles 6 365 Referent Referent 4 281 Referent Referent 
    10 + miles 14 355 2.61 (1.00-6.79) 2.71 (0.59-
12.47) 




        
     < 10 miles 26 1109 Referent Referent 21 1020 Referent Referent 
    10 + miles 24 573 1.75 (1.00-3.05) 1.53 (0.51-4.59) 19 472 1.93 (1.04-3.60) 3.44 (0.91-12.93) 
* Adjusted for age, ER, marital status, income, insurance, treatment, and breast cancer stage at diagnosis 
Interaction: Distance to provider*race=0.69; Interaction: Distance to diagnosing mammography facility= 0.96;Interaction: Distance to 
closest mammography facility= 0.49 








Table 6.4. Crude and Adjusted Hazard Ratios for All-Cause Mortality among Travel Distance 10 + Miles Compared with < 10 
Miles, by Race 



















        
     < 10 miles 34 616 Referent Referent 19 542 Referent Referent 




        
     < 10 miles 12 391 Referent Referent 7 286 Referent Referent 




        
     < 10 miles 39 1160 Referent Referent 40 1067 Referent Referent 
    10 + miles 31 611 1.51 (0.94-2.42) 1.33 (0.50-3.56) 23 490 1.25 (0.75-2.09) 2.59 (0.86-7.86) 
* Adjusted for age, ER, marital status, income, insurance, treatment, and breast cancer stage at diagnosis 
Interaction: Distance to provider*race=0.92; Interaction: Distance to diagnosing mammography facility=0.21 ;Interaction: Distance to 
closest mammography facility= 0.65 
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 Breast cancer is the most commonly diagnosed cancer and is the second cause of 
cancer-related mortality among women in the United States (1). In South Carolina, breast 
cancer is the most common cancer diagnosed and is the second largest cause of cancer 
deaths among women in the state (2). Statewide, the age-adjusted incidence of breast 
cancer from 2002-2006 have remained stable at around 119 per 100,000 women (2), with 
a higher age-adjusted incidence among European American women compared to African 
American women (127.6 and 111.3 per 100,000 women, respectively) (2, 3). However, 
African American women had a 39% higher mortality rate compared to European 
American women (4). This disparity may be due to breast cancer tumor characteristics (5, 
6) and difference in access/utilization of early detection and treatments among African 
American women (7, 8). 
 Early screening is the single most effective method in reducing mortality from the 
disease (1). Annual mammography with adequate follow-up is estimated to result in 
reductions in mortality ranging from 25% to 44% (9-15). Despite the benefit of 
mammography, many women do not maintain annual adherence to screening 





Minority, uninsured, and lower socioeconomic status women often do not have 
access to early detection (19). These women are less likely to utilize mammography 
screening (19-21), less likely to have timely and complete follow-up after an abnormal 
mammography screening (22), more likely to be diagnosed with advanced-stage breast 
cancer (23), and have poorer survival (24). To reduce the disproportionate burden of 
breast cancer among women in South Carolina, the Best Chance Network (BCN) was 
established to offer screening and follow-up services to disadvantaged women in the 
state.   
This dissertation was designed to assess travel distance to the health facilities 
(screening referral provider, diagnosing mammography facility, closest mammography 
facility) and its relationship with completion of abnormal mammography follow-up, 
breast cancer stage at diagnosis, and mortality among women in the BCN program. A 
retrospective cohort study that covers a period of 14 years between 1996 and 2009 was 
used to investigate travel distances (to the screening referral provider, diagnosing 
mammography facility, and closest mammography facility) and completion of abnormal 
mammography follow-up, breast cancer stage at diagnosis, and mortality among women 
in the BCN program.  
In the following pages, the results from each aim are summarized and discussed.  
Aim 1(Chapter 4): Travel distance to screening facilities and completion of 
abnormal mammography follow-up among disadvantaged women 
In aim 1, we examined the relationship between travel distance to the screening 




completion of abnormal mammogram follow-up among women in the BCN program. 
Inadequate screening or incompletion of abnormal mammogram follow-up after an 
abnormal mammogram screening can contribute to poor cancer survival.  Factors 
associated with mammography and inadequate screening have been scrutinized in 
numerous studies, which includes patients characteristics, socioeconomic status, 
insurance status, having a primary health care provider, recommendations for screening 
from primary health care providers, lack of transportation, language barriers, concern 
about the effects of radiation, and fear of cancer (25-30). From a recent review of the 
literature, there has been no study examining distance to the screening referral provider, 
mammography facilities, and its effect on completion of abnormal follow-up. The finding 
from this aim contributes to some of the known factors relating to inadequate breast 
cancer screening. 
We found that women who lived further from their diagnosing mammography 
facility had longer day to resolution (completion of abnormal mammographic finding) 
compared to those who lived the closest (p=0.05). AA women had significantly longer 
day to resolution compared to EA women; the largest difference in median day to 
resolution was in travel distance to the diagnosing mammography facility (28 days for 
AA women vs. 22 days for EA women). We also found that women who lived closest to 
the diagnosing mammography facility were more likely to have an abnormal 
mammographic follow-up completion compared to those who lived the farthest. When 





One important aspect of this aim was our sensitivity analysis using travel distance 
to the diagnosing mammography facility compared with travel distance to the closest 
mammography facility. We observed no association between completion of abnormal 
mammogram follow-up and travel distance to the closest mammography facility, but we 
found an association with travel distance to the diagnosing mammography facility.  
Women were more likely to have their abnormal mammogram follow-up completed if 
they were living closest to their diagnosing mammography facility. Choosing a facility 
for screening may not always be the closest to home due to various factors, such as 
personal preference, neighborhood characteristics, and hours of operation. Relying on the 
closest mammography facility to calculate the travel distance may not portrait an accurate 
distance.   
Aim 2(Chapter 5): Travel distance to screening facilities and breast cancer stage at 
diagnosis among disadvantaged women 
The purpose of this aim was 1) to investigate whether travel distance to the 
screening provider and mammography facility was associated with stage of breast cancer 
at diagnosis, 2) are there racial disparities in breast cancer stage at diagnosis among 
women in BCN, and 3) are there a difference in the distribution of breast cancer stage at 
diagnosis among BCN participants and non-BCN participants? Breast cancer stage at 
diagnosis is an important factor in survival and mortality (1). Women with breast cancer 
diagnosed at advanced stage have limited treatment options and poorer survival 
compared to women with early stage breast cancer. The 5-year relative survival rate 




four times greater than those of women whose cancer has spread to distant (distant stage) 
lymph nodes or organs at the time of diagnosis (84% vs. 23%) (1).   Many studies have 
examined travel time/distance to health care or mammography facility and breast cancer 
stage at diagnosis (31-39); however, findings have been inconsistent between the studies. 
The inconsistent results may be due to geographical locations and density of population 
or mammography facilities in the area. Nevertheless, almost all of these studies used the 
closest mammography facility to calculate the travel distance/time. In our study, we were 
able to use all three health facilities (screening referral provider, diagnosis mammography 
facility, and closest mammography facility).  
In the crude models, we found no significant relationship between travel distance 
and breast cancer stage at diagnosis. However, when we adjusted for age, race, income, 
insurance status, and marital status, we found that women living 10-15 miles from their 
diagnosing mammography facility were 2.25 times (95% CI=1.04-4.83)  more likely to 
be diagnosed with late stage breast cancer compared to those living less than 5 miles 
from their diagnosing mammography facility. We found no association (both in the crude 
and adjusted model) among EA and AA women in the BCN.  
Among women in the BCN, there was no difference in the distribution of cancer 
stages and race (p-value=0.45). However, there was statistically significant difference 
between breast cancer stage at diagnosis and race among non-BCN women (p-
value<0.01), with AA women had higher percentage of regional and distant breast cancer 




 Our null findings, though not what we expected, is similar to six studies that 
found no association between travel distance to the mammography facility and breast 
cancer stage at diagnosis (31-36). From a literature search, there were three studies that 
found an association (37-39). However, all of them used the closest mammography 
facility as the facility of utilization and they used zip code centroids to compute the travel 
distance.  
All of these studies that examined this relationship had no information on 
patients’ mammography utilization. By using the nearest mammography facility, a patient 
may not utilize this facility due to various reasons. Relying on the closest mammography 
facility may underestimate the true travel distance between patients’ residence and actual 
mammography usage if the closest facility is not the one being utilized.  
Aim 3(Chapter 6): Travel distance to screening referral provider, mammography 
facility, and breast cancer mortality among women in a state breast cancer 
screening program 
 In aim 3, we investigated the association between travel distance to the screening 
referral provider, mammography facility, and cancer-specific and all-cause mortality 
among women in BCN. We also contrasted and compared breast cancer-specific and all-
cause survival between European-American and African-American women in BCN. 
Stage at diagnosis, age, race, socioeconomic status, lifestyle, and tumor characteristics 
are all associated with breast cancer mortality and survival (37-45). The association 
between geographic proximity to the screening referral provider, mammography facility, 




 We found no significant difference in the survival proportions for breast cancer-
specific and all-cause among AA and EA women. In the crude model, we found that 
women living 10+ miles from the diagnosing mammography and closest mammography 
facility had ~2-fold increase risk of death from breast cancer compared to those living 
<10 miles. However, we found no association when adjusted for race, age, estrogen 
receptor, marital status, income, insurance, treatment, and breast cancer stage at 
diagnosis. We also found no association between travel distance to the screening referral 
provider, diagnosing mammography facility, closest mammography facility and all-cause 
mortality between EA and AA women. Though we did not find any study that 
investigated travel distance to healthcare facility and breast cancer survival in the United 
States, a study in Northern England had similar finding (46); they found no association 
between travel time to the general practitioners and breast cancer survival. Our finding 
shows that travel distance to the screening referral provider and mammography facility 
may not be a risk factor for breast cancer mortality and survival among women in BCN. 
Since our finding from aim 2 did not find any convincing evidence that travel distance to 
the screening referral provider and mammography facility was associated with breast 
cancer stage of diagnosis, we were not surprised with these null findings. 
Implications  
 This dissertation provides significant contributions to the better understanding of 
geographical level barriers to abnormal mammographic follow-up and breast cancer 
morbidity and mortality, especially in South Carolina. Mammography screening rates 




abnormal mammogram and breast cancer morbidity and mortality are still serious public 
health concerns. The study showed that travel distance from patient residence to the 
diagnosing mammography facility affects completion of abnormal mammographic 
finding; women living farther from the facility had longer days to resolution (completion 
of abnormal mammographic finding) compared to those who living the closest.  This 
study provides a geographical dimension that needs to be considered when developing 
effective intervention to make sure women are having timely abnormal mammographic 
finding. Due to the low-income population of the BCN program, some women may not 
have reliable transportation. Hence, providing transportation, such as a shuttle, for 
patients to and from the facility may be an effective intervention. 
The establishment of BCN was to provide service delivery and ensures timely and 
complete diagnostic follow-up and treatment initiation for underserved women screened 
through the program. Since we found evidence of racial disparity in the time to 
completion of abnormal mammogram work-up (AA women had longer days to 
completion compared with EA women), additional support to the BCN program to 
expand services should be promoted to reduce the disparity in days to completion of 
abnormal mammographic finding among EA and AA women. 
Living farther from the screening referral provider and mammography facility did 
not increase the chance of late-stage breast cancer at diagnosis and mortality among 
women in BCN. There were also no racial disparities in the breast cancer stage at 
diagnosis and mortality among the women. These findings reveal that the program is 




groups. However, the findings in this study may be unique, because our population was 
from a program that was established to provide adequate screening and follow-up among 
women who enter the program; therefore, it may not be generalized to the general 
population.  
Another explanation for these null findings could be related to the geography of 
South Carolina. The state is relatively a rural state and women may seek health services 
no matter the distance. Due to the extensive BCN network providing service throughout 
the state, travel distance may not be an issue for these women; the mean travel distance to 
the screening provider is 10.9 miles (SD=10.5), diagnosing mammography facility is 14.6 
miles (SD=15.8), and closest mammography facility is 8.1 miles (SD=6.5). Overall, this 
study has shed some light on geographical proximity to some of the health facilities and 
completion of abnormal mammographic finding and breast cancer morbidity and 
mortality among women with homogenous socioeconomic status. This study adds to 
some of the breast cancer disparities research in South Carolina. 
Recommendations for Future Research 
 This research is the first study to use geospatial method to examined travel 
distance to the screening provider, mammography facility, and completion of abnormal 
mammography follow-up among a low-income population who have access to screening 
at no cost. It is also one of the few research studies to examined travel distance to the 
screening provider, mammography facility, and breast cancer morbidity and mortality. 
This research measured the distance to mammography facilities using road network. 




considered. Future research that examines the relationship between travel distance to 
mammography facility or health facilities should consider these barriers, because it 
affects travel distance.  Capturing an accurate measurement of travel distance/time will 
help better understand whether location of the health facilities affect health outcome. 
Other important factors to consider are the mode of transportation utilized by patients, 
availability and frequency of transport services, quality of service provided in the 
mammography facilities, and the nature of social constraints related to mammography 
utilization.  
 This study was conducted on a population that came from a relatively rural area. 
The attitude regarding health care services may be different from people living in more 
urban areas. Further study on similar program like the BCN in other geographical 
location and larger study from the general population should be investigated to confirm 
the findings.  
Though this research focused on the geographic aspect (travel distance) from the 
patient’s residence to the health facilities, future research should also seek qualitative 
aspects focusing on the provider-patient communications to follow-up. The patient, 
provider, and system can all contribute to inadequate follow-up and morbidity and 
mortality. A multi-discipline will not deepen our knowledge about barriers affecting 
completion of abnormal mammographic finding and breast cancer morbidity and 
mortality, but it may also suggest avenues of intervention to decrease the health 
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